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The aryl hydrocarbon receptor (AHR), also known as the dioxin receptor, was originally 
characterized as a xenobiotic receptor that senses xenotoxicants. In the first part of my thesis 
research, I have uncovered an unexpected endobiotic and hepatic role of AHR in fatty liver and 
energy metabolism. Despite causing severe fatty liver, transgenic activation of AHR protected 
mice from diet-induced obesity and type 2 diabetes. The endocrine hormone fibroblast growth 
factor 21 (FGF21) was established as a novel transcriptional target of AHR and mediates the 
metabolic benefit of AHR. Moreover, the transactivation of FGF21 by AHR contributed to both 
hepatic steatosis and systemic insulin hypersensitivity, both of which were largely abolished 
upon FGF21 knockdown. Results from this study may help to establish AHR as a pivotal 
environmental modifier that integrates signals from chemical exposure in the regulation of lipid 
and energy metabolism.  
The second part of my thesis research is to investigate the function of AHR in promoting 
hepatic carcinogenesis and to study the mechanisms of its tumor-promoting effect. 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), or dioxin, is a potent liver cancer promoter through 
sustained activation of AHR in rodents, but its carcinogenic effect in human has been 
controversial. This inter-species difference is largely due to different ligand affinity and distinct 
gene transactivation selectivity and potency. Here I report the oncogenic potential of human 
AHR in promoting hepatic carcinogenesis. Constitutive activation of human AHR was as 
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efficiently as mouse Ahr in promoting diethylnitrosamine (DEN)-initiated hepatic carcinogenesis 
in transgenic mice. The growth arrest and DNA damage-inducible gene 45 beta (Gadd45b), a 
signal molecule inducible to external stress and UV irradiation, is highly induced upon AHR 
activation and acts as a transcriptional target of AHR. In addition, as an intrinsic coactivator, 
Gadd45b facilitates the AHR transcription activity, which might play a role in potentiating the 
tumor promoting effect of AHR.  
Taken together, my work has revealed critical functions of AHR in energy homeostasis 
and hepatic carcinogenesis. It is hoped that understandings of the functions of AHR may help 
develop AHR-based novel therapeutics in the treatment of metabolic diseases and hepatic 
carcinogenesis. 
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1.0  CHAPTER I: INTRODUCTION 
1.1 ARYL HYDROCARBON RECEPTOR AS A XENOBIOTIC SENSOR  
 
 
Figure 1. Mechanism of classical Aryl hydrocarbon receptor (AHR) action.  
AHR is retained in the cytoplasm in a complex with X-associated protein 2 (XAP2) and two heat shock 
protein 90 (HSP90) molecules in the absence of AHR ligands. Ligand binding triggers their nuclear 
translocation and causes conformational change and as a result, the AHR nuclear translocator (ARNT) 
binds to AHR and forms a functional heterodimer. This heterodimer binds to the dioxin response element 
(DRE) located in the promoter regions of AHR targets, such as CYP1s, therefore inducing their 
transcription and causing drug metabolism.  
 
Exposures to xenobiotics such as environmental chemicals and drugs have profound influence on 
human health. The induction of xenobiotic metabolizing enzymes in response to chemical insults 
is an adaptive response found in most organisms. The detoxification and clearance of these 
 2 
xenobiotics are accomplished by the concerted action of Phase I cytochrome P450 (CYP) 
enzymes, Phase II conjugating enzymes, and drug transporters (1). The P450 enzymes catalyze 
the monooxygenase reactions of lipophilic compounds facilitated by the reducing power of the 
NADPH P450 oxidoreductase (2, 3). Phase II enzymes are several large group of transferases, 
such as sulfotransferase (SULT), glutathione S-transferase (GST), and UDP-
glucuronosyltransferase (UGT), which conjugate polar functional groups onto xenobiotics (4). 
Finally, the members of ABC transporter proteins and solute carrier family act to mediate the 
excretion process (5). Although in most cases, the biotransformation of xenobiotics leads to 
pharmacologically inactive metabolites, it may also activate so-called pro-drugs to 
pharmacologically active products or even to toxic metabolites (6).  
Most drug-metabolizing enzymes are inducible in response to xenobiotics (7, 8). 
However, the molecular basis underlying this drug-induced metabolism remained largely 
unknown for a long time. Discovery of xenobiotic receptors stemmed from the concept that 
xenobiotic induction was mediated by a receptor through a transcriptional machinery, which is so 
called “induction-receptor” hypothesis. The plausibility of this hypothesis took a great leap 
forward with the discovery of the dioxin receptor or the aryl hydrocarbon receptor (AHR) in 
1976 (9). AHR is a ligand-activated transcription factor that belongs to the basic helix–loop–
helix-PER-ARNT-SIM (bHLH-PAS) subgroup of the bHLH superfamily (10). It is widely 
expressed in the body and evolutionarily conserved from invertebrates onwards, but its activity is 
tightly regulated (11). Upon binding to its agonists, such as 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) or 3-methylcholanthrene (3-MC), AHR dissociates from its cytoplasmic complex 
and translocates into the nucleus, forms a heterodimer with its partner AHR nuclear translocator 
(ARNT), binds to dioxin response elements (DREs) located in the promoter of its target genes, 
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and activates their transcription (Fig. 1). The sustained hyperactivation of AHR can result in a 
myriad of toxicological outcomes (12). Examples of AHR target genes include several P450 
enzymes that are important in drug metabolism and bioactivation, such as CYP1As and 
CYP1B1, and Phase II UGT1As (8, 13).  
Although AHR was identified as a xenobiotic receptor, emerging evidence has pointed to 
an equally important role of AHR as an endobiotic receptor. DNA microarray studies have 
established a large number of genes that are regulated in an AHR-dependent manner. These gene 
products are involved in a wide variety of biochemical pathways, including energy metabolism, 
lipid and cholesterol synthesis, and transportation pathways (14). The evidence that AHR null 
mice showed impairment in normal development of liver, immune system, heart, and vascular 
tissues also provide insights into the physiological functions of AHR beyond mediating 
xenobiotic metabolism (15-18).  
1.2 MECHANISMS OF AHR ACTIVATION 
1.2.1 AHR Ligands 
The characterization of high-affinity ligands for AHR, including xenobiotics such as persistent 
planar halogenated polycyclic hydrocarbons (HAHs) (dioxins, dibenzofurans, and biphenyls) and 
polycyclic aromatic hydrocarbons (PAHs) (benzo[a]pyrene (BaP) and benzanthracene), has been 
the focus for many years. HAHs, the best-characterized and highest affinity prototype ligands 
(with binding affinities in the pM to nM range) of the AHR, are poorly metabolized. In contrast, 
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PAHs and PAH-like chemicals are readily metabolized by the action of CYPs, which may 
convert them into reactive metabolites (19). 
The evidence that AHR signaling pathway is active in the absence of exogenous ligands 
suggests the existence of endogenous physiological AHR ligands (20, 21). Diet contains the 
greatest source of AHR agonists or products that can be readily converted to agonists, and this 
could substantially contribute to our AHR action levels (15). For example, extracts of vegetables 
and several dietary plant compounds (such as curcumin, 7,8-dihydrorutacarpine, 
dibenzoylmethanes, and carotinoids) were reported to exert AHR activation potential (15). 
Tryptophan derivatives are a major group of endogenous AHR ligands. UV illumination can 
convert tryptophan to its photoproduct 6-formylindolo[3,2-b]carbazole (FICZ), which exhibits a 
more potent AHR agonist activity (22). Bacteria in the intestinal tract can metabolize tryptophan 
into indole metabolites (such as indole-3-carbinol, indolo [3,2-b]-carbazole, indole-3-acetate, etc.) 
with AHR-inducing activities (15, 23, 24). The tryptophan metabolite kynurenine, which can be 
generated by the enzymes indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase 
(TDO), were shown to be present in large amounts in human brain tumors with AHR-activating 
effect (25). Indigo and indirubin, which are also tryptophan-derived metabolites by P450 
enzymes action, were identified in human urine as a potent activator of the AHR (15). Other 
endogenous ligands such as tetrapyroles and arachidonic acid derivatives have also been shown 
to activate the AHR (26, 27).  
1.2.2 Mechanisms of AHR Action 
Classical AHR- and DRE-dependent mechanisms mediate most of the toxic and biological 
effects caused by TCDD and other AHR ligands. In the absence of ligands, AHR exists in a 
 5 
multi-protein complex comprising of two heat shock protein 90 (HSP90) molecules and a HBV 
X–associated protein 2 (XAP2) (Fig. 1) (8, 28). Upon ligand binding, the AHR complex 
undergoes a conformational change and translocates into the nucleus. Once in the nucleus, the 
dimerization between AHR and its partner ARNT results in the dissociation of other binding 
proteins from the AHR complex (15). The AHR/ARNT heterodimer binds to the DREs (their 
consensus sequence being “GCGTG”) located on the promoters of AHR responsive genes, 
leading to coactivator recruitment and transcriptional activation of genes. Nuclear export of AHR 
into the cytosol is mediated by its N-terminal nuclear export sequence followed by ubiquitin-
mediated AHR proteosomal degradation (29). 
Although the AHR responsive genes for its xenobiotic and biological effects remain to be 
identified, studies using mice with deletion of AHR or ARNT clearly demonstrated that the 
AHR/ARNT functional heterodimer was required for TCDD-induced phenotypic changes in 
mice (30). In addition, mice were found resistant to the TCDD-induced toxicity when carrying 
the mutation in the nuclear localization sequence or in the DNA-binding domain of the AHR, 
demonstrating that both the AHR nuclear localization and DRE binding are required for the toxic 
and biological effects of TCDD (31, 32).  
As a transcription factor, AHR can crosstalk with other nuclear receptors through protein-
protein interaction and/or DNA-protein interaction. The best understood example is the crosstalk 
between the AHR and estrogen receptor (ER) signaling pathways (33). Several mechanisms 
account for the AHR-ER crosstalk. For example, AHR/ARNT complex could bind to the 
inhibitory DREs, leading to the blockade of ER binding to its estrogen response element (ERE) 
on the gene and resulting in repressed estrogen response. AHR can also compete with ER in 
recruiting common coactivators (such as p300/CBP, SRC1/2, and RIP140) for both receptors, 
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leading to reduced available coactivators for ER transcriptional activity (33). Similar mutual 
repressive crosstalk has also been observed between AHR and intracellular signaling pathways. 
For example, the inhibitory crosstalk between AHR and NF-κB pathway can be caused by the 
formation of transcriptionally inactive AHR/RelA dimer, as well as competition for common 
coactivators (19). CYP1s-induced metabolism of exogenous and endogenous chemicals can lead 
to generation of reactive oxygen species and oxidative stress, which alters cellular responses via 
activating intracellular kinases (19). 
The TCDD-induced effects in an AHR-independent manner could be achieved through 
increasing the intracellular calcium levels. This induction of calcium influx by TCDD could 
cause the activation of a variety of signaling pathways including protein kinase C (PKC), 
epidermal growth factor receptor (EGFR), mitogen-activated protein kinase (MAPK), etc., all of 
which contribute to the complexity and diversity of the nongenomic action of TCDD (19).  
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2.0  CHAPTER II: ENDOBIOTIC FUNCTION OF AHR IN LIPID AND ENERGY 
METABOLISM 
2.1 OVERVIEW OF LIPID AND ENERGY METABOLISM 
2.1.1 Fatty Acid and Triglyceride Metabolism   
The liver is the hub of fatty acid synthesis and triglyceride storage. The liver integrates incoming 
signals to control triglyceride production for use by other tissues and for storage in adipose 
tissues. Triglycerides are the preferred storage nutrient to buffer against fluctuations in energy 
demands and availability. Hepatic steatosis, or fatty liver, is defined as the presence of 
cytoplasmic triglyceride droplets in more than 5% of hepatocytes (34). Fatty liver is commonly 
associated with metabolic syndromes including obesity and type 2 diabetes and can lead to 
inflammation, fibrosis, and even cirrhosis and cancer.  
Steatosis may develop as a consequence of multiple dysfunctions. The fatty acids used 
for hepatic triglyceride formation originate from de novo synthesis, diet, and adipose tissue. 
Carbohydrate feeding promotes de novo lipogenesis by inducing the key enzymes involved in 
this pathway such as the fatty acid synthase (FAS), stearoyl CoA desaturase 1 (SCD-1), and 
acetyl coenzyme A carboxylase 1 (ACC-1), all of which are under the transcriptional control of 
the master lipogenic transcriptional factor sterol response element binding protein-1c (SREBP-
 8 
1c). Lipoprotein lipase (LPL) and adipocyte triglyceride hydrolase (ATGL) catalyze the 
hydrolysis of the triglyceride in the chylomicrons and adipocytes, respectively; thereby releasing 
free fatty acids into the circulation. The liver takes up free fatty acids via the fatty acid transport 
protein (FATP) or fatty acid translocase (FAT/CD36) when there is an excess of circulating fatty 
acids. Once in the liver, fatty acids can be oxidized to produce energy and ketone bodies, re-
esterified to triglyceride, or exported as very-low-density lipoproteins (VLDL). Carnitine 
palmitoyltransferase 1 (CPT1) and mitochondrial 3-hydroxy-3-methylglutarate-CoA synthase 
(HMGCS) are two key enzymes in β-oxidation and ketogenesis. Apolipoprotein B100 (ApoB100) 
is the key component that controls the overall rate of VLDL production and secretion (35). In 
summary, steatosis may arise from an imbalance between triglyceride acquisition and removal 
due to increased fatty acid synthesis and uptake, decreased fatty acid β-oxidation, and reduced 
triglyceride secretion.  
2.1.2 Glucose and Insulin Metabolism 
Plasma glucose levels are strictly regulated in normal individuals, which process is controlled by 
the actions of insulin and glucagon. Circulating glucose is derived from three sources: intestinal 
absorption, gluconeogenesis, and glycogenolysis, and its levels are maintained by glucose 
appearance and removal. Insulin is the only pancreatic β-cell hormone that can lower the glucose 
levels. Following feeding, insulin is secreted and acts on skeletal muscle through binding to the 
insulin receptor and increases glucose uptake through the action of glucose transporters such as 
glucose transporter 4 (GLUT4). On the other hand, insulin exerts its effect on liver to trigger 
glycogenesis, in which glucose molecules are added to chains of glycogen for storage. Finally, 
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insulin represses the secretion of glucagon from pancreatic α-cells, thus blocking 
gluconeogenesis and glycogenolysis in the liver.  
Abnormal action of insulin is the foundation of the pathophysiology in diabetes. Type 1 
diabetes is characterized by the dysfunction of pancreatic β-cells in producing insulin, whereas 
Type 2 diabetes is associated with peripheral insulin resistance in the early stage followed by 
progressive β-cell failure during the late stage. Insulin resistance, a pathological condition in 
which cells fail to respond to the normal actions of insulin, is a major feature of Type 2 diabetes.  
Particularly, insulin resistance can lead to nonalcoholic fatty liver disease (NAFLD) by 
increasing lipolysis in adipose tissue and facilitating fatty acid uptake into the liver, inducing 
hepatic de novo lipogenesis, and decreasing the fatty acid β-oxidation (36). Liver fat 
accumulation, on the other hand, is believed to generate elevated levels of free fatty acids and 
pro-inflammatory lipid intermediates that can disrupt the insulin signaling cascade and cause 
insulin resistance (37). However it remains uncertain whether a causal relationship exists.  
2.2 AHR IN LIPID AND ENERGY METABOLISM 
2.2.1 AHR in NAFLD and NASH 
It has long been suggested that the systemic TCDD toxicity involves an overall perturbation of 
energy homeostasis (38). Earlier work associated exposures to AHR agonists with dyslipidemia 
by reporting that TCDD and related halogenated aromatic hydrocarbons (HAHs) produced 
marked fatty liver in several species (39-41). In agreement with these animal results, dioxin 
exposure in human populations has also been reported to be associated with increased incidence 
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of fatty liver (42). The accumulation of hepatic triglycerides was accompanied by an increase in 
liver weight and liver to body weight ratios (43). Increased de novo fatty acid synthesis (44), 
decreased fatty acid oxidation (45), and increased half-life of liver lipid moieties (43) have been 
suggested to account for the hepatic steatosis in AHR agonist-treated rats. In contrast, some other 
studies have shown decreased hepatic fatty acid synthesis in both animal models and primary 
human hepatocytes upon TCDD treatment, which was associated with reduced expressions of 
key lipogenic genes including FAS, SCD-1, and acetyl-CoA carboxylase (46-48).  
One needs to be cautious when interpreting these phenotypes because TCDD itself is 
toxic to the cells and animals. AHR function has also been studied by overexpressing a 
constitutively active AHR in which the ligand-binding domain has been deleted. Recently, we 
showed that mice overexpressing a constitutively activated mouse Ahr (CA-Ahr) in the liver 
developed a spontaneous steatosis without causing a general hepatotoxicity. The steatosis in CA-
Ahr transgnenic mice was manifested by increased fatty acid uptake and decreased VLDL-
triglyceride secretion. CD36, the fatty acid translocase, was identified as a novel AHR target 
gene that mediated the steatotic effect (49). In another independent study, mice fed with the 
AHR ligand 3-MC, an AHR agonist less toxic than TCDD, showed a hepatosteatotic phenotype 
through a similar mechanism (50). 
Using the same CA-Ahr transgenic mice, we showed that activation of Ahr also 
sensitized mice to non-alcoholic steatohepatitis (NASH), an advanced stage of NAFLD with the 
hallmarks of inflammation and progressive fibrosis (51). The CA-Ahr transgenic mice showed 
heightened sensitivity to methionine and choline deficient diet (MCD)-induced NASH by 
decreasing the activity of superoxide dismutase 2 (SOD2) and increasing mitochondrial reactive 
oxygen species (ROS) production in the liver. Mechanistically, the mitochondrial sirtuin 
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deacetylase Sirt3, which could enhance the scavenging of superoxide through activating the 
mitochondrial SOD2, was inhibited by Ahr. The Ahr-responsive inhibition of Sirt3, a NAD+ 
dependent deacetylase, was likely due to the depletion of the cellular concentration of NAD+ 
because of the activation of TiPARP by Ahr (52). Sensitization of mice to the MCD diet-induced 
NASH was also demonstrated in WT mice treated with TCDD. Interestingly, the anti-oxidative 
role of Ahr has also been reported. For example, the nuclear factor erythroid 2 related factor 2 
(Nrf2), a master regulator of anti-oxidative responses, was directly induced by AHR activation, 
which in turn protected against the oxidative stress (53). Other reported AHR inducible 
cytoprotective genes include the NAD(P)H:quinone oxidoreductase 1 (Nqo1), GSTs, and UGTs 
(54). These results suggested that AHR might have a rather complex role in liver’s handling of 
oxidative stress.  
2.2.2 AHR in Type 2 Diabetes and Insulin Resistance 
Dyslipidemia is a well-known predisposing factor for the development of type 2 diabetes. With 
the potential effects of AHR on dyslipidemia, it is reasonable to hypothesize that AHR can affect 
the pathogenesis of diabetes as well. Indeed, both animal models and human studies suggested an 
association between TCDD exposure and increased incidence of diabetes (55-57), but the 
underlying mechanism is poorly defined. TCDD-induced reduction in glucose uptake has been 
reported in adipose tissue, liver, and pancreas (58-60), primarily through the decreased 
expression of GLUT4 (61). Another suggested mechanism was the inhibition of hepatic 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase), which 
resulted in an impairment of gluconeogenesis (62). In a human study, non-diabetic veterans with 
high blood TCDD levels were found to more likely develop insulin resistance (63). TCDD-
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treated animals showed β cell dysfunction, including reduced insulin production and secretion 
(59, 64). Based on the fact that loss of PPARγ is diabetogenic, and the PPARγ agonists 
thiazolidinediones sensitize tissues to the insulin actions, it was also suggested that the 
diabetogenic effects of TCDD might be through antagonizing the PPARγ functions (55). The 
direct link between AHR and diabetes and insulin resistance has been reported using the AHR-
null mice, which displayed enhanced insulin sensitivity and improved glucose tolerance in both 
normal chow diet- and high fat diet-fed conditions (65, 66). But the mechanisms underlying its 
metabolic effects in insulin resistance need to be evaluated.  
The AHR heterodimerization partner ARNT, also known as hypoxia-inducible factor 1β 
(HIF1β), is a ubiquitously expressed nuclear protein that also belongs to the bHLH/PAS family 
of transcription factors (67). Recent findings showed that the expression of ARNT was reduced 
in both liver and β cells of obese individuals with type 2 diabetes (68, 69), suggesting an 
important role of ARNT in the development of metabolic disease. Further studies demonstrated 
that the deficiency of ARNT activity in β cells and liver contributed to impaired insulin secretion 
and dysregulation of glucose homeostasis, respectively (68, 69).  
Insulin resistance is associated with elevated plasma levels of very-low-density 
lipoprotein (VLDL) and low-density lipoprotein (LDL) (70, 71). Subsequent atherosclerotic 
lesion is a serious cause for the cardiovascular complications arisen in the patients with type 2 
diabetes. A significant positive correlation between high serum TCDD and plasma cholesterol 
and triglyceride levels was observed in subjects exposed to chloracne, and among US Vietnam 
war veterans who had been exposed to high levels of TCDD (72-74). A follow-up study on a 
cohort of former TCDD workers showed that exposure to TCDD caused atherosclerotic plaques 
and ischemic heart disease (75). Animal studies confirmed that TCDD induced a marked 
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dyslipidemia characterized by increased total cholesterol, VLDL, LDL, and triglyceride levels 
(76-78). Mechanistically and of particular relevance to triglyceride metabolism, the adipose 
activity of LPL, which hydrolyses triglyceride and promotes its cellular uptake, was reduced in 
both animals and adipocyte cultures after TCDD treatment (60, 79). As for the cause of 
hypercholestenolemia, TCDD caused a down-regulation of LDLR on the plasma membrane of 
hepatocytes, leading to a decreased cholesterol internalization and elevated levels of plasma 
cholesterol (80). However, it remains to be determined whether the effect of TCDD on the 
expression of adipose LPL and liver LDLR is AHR dependent. The effects of AHR on energy 
metabolism are summarized in Figure 2. 
Particularly, having known that activation of AHR causes spontaneous fatty liver (49), it 
is paradoxical to note that TCDD seemed to induce the expression of fibroblast growth factor 21 
(FGF21) (81), a systemic insulin sensitizer. FGF21 is an atypical member of the FGF family 
produced predominantly in the liver (82). FGF21 is induced in the liver by fasting through the 
activation of the peroxisome proliferator-activated receptor α (PPARα) (83, 84). FGF21 exhibits 
many metabolic benefits, ranging from reducing body weight to alleviation of hyperglycemia 
and insulin resistance, and improvement of lipid profiles (85). In hepatocyte and adipocyte, 
FGF21 directly regulates metabolism through interactions with FGF receptor 1 (FGFR1) and 
βKlotho (86). Adiponectin plays an important role in coupling FGF21 actions in adipocytes to 
liver and skeletal muscle, thereby mediating the systemic effects of FGF21 on energy 
metabolism and insulin sensitivity (87). Although FGF21 was shown to be regulated by TCDD, 
the pathophysiological relevance of this regulation remains undefined. Therefore, the 
experiments described in this chapter were designed to investigate the endobiotic and hepatic 
 14 
function of AHR in lipid and energy homeostasis, and to identify the potential contribution of 
FGF21 in these processes.  
2.3 SPECIFIC AIMS 
Although we know that AHR activation in transgenic mice induces spontaneous fatty liver, the 
metabolic effects of AHR in dietary induced fatty liver and associated metabolic syndromes such 
as obesity and insulin resistance has not been addressed. Meanwhile, having noticed that TCDD 
induced FGF21 production, it is interesting to study the relative contribution of FGF21-
dependent pathways in AHR-induced metabolic phenotypes. Therefore, we aim to investigate the 
metabolic outcomes of AHR activation using the gain-of function CA-AHR transgenic mouse 
model, and determine the metabolic changes by using loss-of function of FGF21.  
Aim 1: To determine the role of human AHR in dietary induced fatty liver and 
associated metabolic syndromes such as obesity and insulin resistance. 
Aim 2: To explore the transcription regulation of FGF21 by AHR activation in the 
context of both chow diet- and high fat diet-fed conditions.  
Aim 3: To investigate the contribution of FGF21 transactivation in AHR-mediated 
metabolic effects using FGF21 knockdown.  
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2.4 METHODS 
Mice and Diets 
AHR knockout (AHRKO) mice in C57BL/6 background were purchased from Taconic (Hudson, 
NY). Mice were fed with standard chow from PMI Nutrition (St. Louis, MO) or high fat diet 
(HFD) (S3282) from Bio-serv (Frenchtown, NJ). In the HFD model, 6-week-old mice (N=5 for 
each group) received HFD for 12 weeks in most of the experiments, except that when adenovirus 
were used, mice were treated with HFD for 6 weeks before viral infection. Body weights were 
monitored during HFD feeding and tissues were collected and analyzed at the end of the feeding. 
When necessary, doxycycline (DOX; 1 mg/ml) was given in drinking water. The food intake was 
measured for 7 days after 10 weeks of HFD feeding, and the data was normalized to lean content 
of body weight. Body composition was analyzed using EchoMRI-100TM from Echo Medical 
Systems (Houston, TX). The use of mice in this study complied with relevant federal guidelines 
and institutional policies. 
 
Short Hairpin Adenoviral Production 
Entry clones targeting either FGF21 or LacZ were gifts from Dr. Eleftheria Maratos-Flier (Beth 
Israel Deaconess Medical Center) (83). To generate shRNA expression clones, FGF21 and LacZ 
entry vectors were used to perform LR recombination with the E1- and E3-deleted pAd/BLOCK-
iT-DEST vector from Invitrogen. Adenoviruses were generated by transfecting 293A cells with 
vectors digested with PacI. After plaque selection and amplification, viruses were purified on a 
discontinuous CsCl gradient. Mice received adenovirus intravenously at the dose of 2×109 viral 
particle/g body weight. 
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H&E and Oil Red O staining 
For H&E staining, tissues were fixed in 10% buffered formalin, embedded in paraffin, sectioned 
at 5 μm, and stained with hematoxylin and eosin. For Oil Red O staining, snap-frozen liver 
tissues were sectioned at 8 μm, fixed in 10% buffered formalin, and stained in 0.5% Oil Red O in 
propylene glycerol. The histology was determined under microscopy.  
 
Serum and Tissue Biochemical Analysis 
Serum levels of triglyceride and cholesterol (Stanbio Laboratory, Boerne, TX), ALT and AST 
(Stanbio Laboratory, Boerne, TX), insulin (Crystal Chem, Downers Grove, IL), IL-6, FGF21, 
and Adiponectin (R&D Systems, Minneapolis, MN) were measured by using commercial assay 
kits. To measure serum lipid levels, 75 μl of methanol was mixed with 25 μl of serum and 
centrifuged at 15,000 g for 20 min. To measure hepatic lipid contents, liver tissues were 
homogenized and lipids were mixed with chloroform/methanol (3:1, v/v) and centrifuged at 
3,000 g for 10 min. The organic phase was transferred to a glass tube and dried under a gentle 
stream of nitrogen. The residue was reconstituted by acetonitrile: water (1:1, v/v) and subject to 
measurement. Triglyceride and cholesterol levels were measured at 500 nm using a PerkinElmer 
plate reader. Free fatty acid (FFA) levels were analyzed using the UPLC-QTOFMS methods. 1.0 
µg/ml of internal standards of different species of FFAs-d31 (myristic acid, palmitic acid, 
palmitoleic acid, steric acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, 
eicosapentaenoic acid, docosahexaenoic acid, and eicosanoic acid) were added into serum or 
tissue homogenates before lipid extraction. Chromatographic separation of metabolites was 
performed on an Acquity UPLC BEH C18 column (2.1 × 100 mm, 1.7 µm, Waters). The mobile 
phase A was 0.1% formic acid in acetonitril: water (6:4, v/v), and mobile phase B was 0.1% 
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formic acid in acetonitrile: isoproponal (1:9, v/v). The gradient for aqueouse extraction began at 
35% MPB and held for 1 min, followed by 10-min linear gradient to 95% MPB, held for 3 min 
and decreased to 35% MPB for column equilibration. The flow rate of mobile phase was 0.40 
ml/min and the column temperature was maintained at 50 °C. The Waters Synapt G2-S 
QTOFMS system (Milford, MA) was operated in high resolution mode (resolution ~ 20,000) 
with electrospray ionization. The source and desolvation temperatures were set at 150 and 500 
°C, respectively. Nitrogen was applied as the cone gas (50 l/h) and desolvation gas (800 l/h).  
Argon was applied as collision gas. The capillary and cone voltages were set at 0.8 kV and 40 V. 
The data were acquired in both positive and negative ionization mode. QTOFMS was calibrated 
with sodium formate and monitored by the intermittent injection of lock mass leucine encephalin 
(m/z = 556.2771) in real time. Product ion scans with collision energy ramping from 15 to 50 eV 
were used for structural elucidations of metabolites.   
 
Indirect Calorimetry, Glucose Tolerance Test (GTT), and Insulin Tolerance Test (ITT) 
Indirect calorimetry was performed using the Oxymax Indirect Calorimetry System (Columbus, 
OH). Mice were individually housed in the chamber with a 12 h light and 12 h dark cycle and 
monitored over a 48 h period. For GTT, mice were fasted for 12 h before receiving an 
intraperitoneal injection of D-glucose at 2 g/kg body weight. For ITT, mice were fasted for 6 h 
before receiving an intraperitoneal injection of insulin at 0.5 units/kg body weight. Blood 
glucose concentrations were measured by sampling from the tail.  
 
Western Blotting Analysis 
Tissues were lysed in RIPA buffer supplemented with protease inhibitors. Protein samples were 
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resolved by SDS-PAGE gel, transferred to a polyvinylidene fluoride membrane, and blotted with 
antibodies. The primary antibodies used include those against AHR (N-19, Santa Cruz), 
pThr172AMPKα (cat# 2535, Cell Signaling) and total AMPKα (cat# 260, Cell Signaling), 
FGF21 (cat# 171941, Abcam), ApoB100 (H-15, Santa Cruz), and β-actin (A1978, Sigma). 
 
Electrophoretic Mobility Shift Assay (EMSA), Chromatin Immunoprecipitation (ChIP) 
Assay, Transient Transfection and Luciferase Reporter Assay 
EMSA was performed using 32P-labeled oligonucleotides and receptor proteins prepared by the 
TNT method (88). ChIP assays for the human and mouse FGF21 promoters were performed on 
293 cells transfected with pCMX-Flag-CA-AHR plasmid for 24 h and WT mice whose livers 
were transfected with the pCMX-Flag-CA-AHR plasmid by a hydrodynamic gene delivery 
method for 8 h (88), respectively. Cells or liver lysates were immunoprecipitated with the anti-
Flag antibody (Sigma). The recovered DNA was assayed for enrichment of the FGF21 promoters 
by PCR. For luciferase reporter assay, the human FGF21 reporter plasmids (-2124/+29, -
1836/+29, and -1562/+29) were PCR-amplified. The mouse FGF21 reporter plasmids (-98/+5 
and -66/+5) were gifts from Dr. Steven A. Kliewer (UT Southwestern Medical Center) (84). 
HepG2 cells were transfected with the reporter construct and AHR or CA-AHR expression 
vector in triplicate groups in 48-well plates. When necessary, cells were treated with 3-MC (4 
μM) or TCDD (10 nM) for 24 h before reporter assay. The transfection efficiency was 
normalized against the β-galactosidase activities from a co-transfected CMX-β-galactosidase 
vector. 
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VLDL Secretion Assay 
Mice were fasted for 4 h before receiving an intravenous injection of tyloxapol, a lipoprotein 
lipase inhibitor at 500 mg/kg body weight. Tail vein blood samples were collected at 0, 60, and 
90 min after the tyloxapol injection, and plasma triglyceride levels were measured at 500 nm 
using a PerkinElmer plate reader. 
 
Tissue Mitochondrial Fatty Acid Oxidation 
Liver and skeletal muscle mitochondrial fatty acid oxidation was measured as described 
previously (89). Fresh tissues were excised and placed in ice-cold modified Chappell-Perry 
buffer. Tissues were homogenized and mitochondria were isolated using differential 
centrifugation. Oxidation assays were performed using 0.2 mM [14C]-oleate. Reactions were 
terminated by adding 100 μl of 70% perchloric acid, and [14C]-CO2 was trapped in 200 μL of 1 N 
NaOH. [14C]-CO2 and [
14C]-labeled acid-soluble metabolites (ASM) were assessed by liquid 
scintillation counting. 
 
Quantitative RT-PCR 
Total RNA was extracted using TRIzol and subjected to reverse transcription with random 
hexamer primers and Superscript RT III enzyme (Invitrogen). SYBR Green-based qRT-PCR was 
performed with the ABI7500 System. Data were normalized against the cyclophilin control.  
 
Statistical Analysis 
When applicable, results are presented as means ± standard error of the mean (SEM). Statistical 
significance between the means of two groups was analyzed using an unpaired Student t test, and 
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analysis of variance (ANOVA) for the comparison among the means of three or more groups. 
Differences were considered statistically significant at P < 0.05. Repeated-measures ANOVA 
was used to compare means of two or more groups across multiple time points (body weight 
monitoring study).   
2.5 RESULTS 
2.5.1 Creation and Characterization of the Constitutively Activated AHR (CA-AHR) 
Construct 
Previous study has shown that CA-mAhr is constitutively activated if it lacks the region of the 
ligand-binding domain (amino acids 287-422) (90). To study the function of human AHR, we 
constructed a constitutively activated human AHR (CA-AHR) by similarly deleting the minimal 
ligand-binding domain (amino acids 273-432) of AHR (Fig. 2A). Functionality of the CA-AHR 
construct was determined in CV-1 cells (normal African green monkey kidney fibroblast cells) 
transiently transfected with the DRE-driven luciferase reporter construct pGud-Luc, together 
with expression constructs of AHR or CA-AHR and ARNT. As shown in Figure 2B, CA-AHR 
dramatically increased the pGud luciferase activity in the absence of an AHR ligand, and 
addition of the agonist ligand 3-MC had no further effect. In contrary, the wild type AHR 
exhibited ligand-dependent activation effect as shown by Fig. 2B. When mice liver were 
transfected with CA-AHR construct by a hydrodynamic gene delivery system, hepatic mRNA 
expression of AHR-responsive genes including CYP1A1 and CYP1B1 was significantly induced 
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without a ligand treatment (Fig. 2C). Thus, CA-AHR transgene is transcriptionally active with 
ligand-independent manner in both in vitro and in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Characterization of the constitutively activated AHR (CA-AHR) construct.  
(A) Schematic representation and domain structure of the wild type (WT) AHR and constitutively 
activated AHR (CA-AHR). bHLH, helix-loop-helix; PAS, PER-ARNT-SIM; TAD, transactivation 
domain. (B) CA-AHR activates the AHR-responsive pGud-Luc reporter in a ligand independent manner. 
CV-1 cells cultured in 48-well plates were transfected with CMX (cytomegalovirus-based)-PL2 empty 
vector or AHR, CA-AHR, and ARNT (AHR nuclear translocator) expressing plasmids at 50ng/well 
concentrations for 6 hours before the treatment with 3-methylchoranethrene (3-MC) (4 μM). After 24 
hours, cells were lysed and subject to luciferase reporter assay in triplicate groups.  (C) Eight week-old 
CD-1 male mice were hydrodynamically delivered with 5μg of the AHR or CA-AHR plasmids. Mice 
were sacrificed 16 h later, the livers were collected and the expressions of CYP1A1 and CYP1B1 were 
measured by RT-PCR. N=5 for each group. Results are presented as means ± standard error of the mean 
(SEM). 
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2.5.2 Generation of Conditional Tetracycline Inducible Transgenic Mice Expressing CA-
AHR in the Liver  
To study the in vivo function of human AHR, we generated the “Tet-off” tetracycline inducible 
FABP-tTA/TetRE-CA-AHR transgenic mice overexpressing the CA-AHR in the liver under the 
control of the fatty acid binding protein (FABP) gene promoter (Fig. 3A). Our “Tet-off” 
transgenic system is composed of two transgenic lines: TetRE-CA-AHR and FABP-tTA lines. 
To generate the TetRE-CA-AHR transgenic line, CA-AHR was placed downstream of a minimal 
cytomegalovirus promoter fused to the tetracycline responsive element (TetRE). The 
functionality of TetRE-CA-AHR construct was analyzed by reporter assay, in which TRE-CA-
AhR and pGud-Luc constructs were transiently transfected, together with CMX-tTA that express 
the tTA in CV-1 cells (Fig. 3B). Coexpression of tTA with TRE-CA-AHR resulted in induction 
of pGud luciferase activity in the absence of doxycycline (DOX), however with DOX treatment 
there was no stimulation of luciferase activity (Fig. 3B). Pronuclear microinjection of the TetRE-
CA-AHR into the C57BL/6 embryos was performed at the University of Pittsburgh Transgenic 
Core Facility. The genotyping for TetRE-CA-AHR mice was performed by PCR using primers 
for TRE1-5’- (GAGCTCGTTTAGTGAACCGTCA) and CA-AHR-3’-(AGACCAGTGGCTTC 
TTCAATTCC). The liver-specific FABP-CA-AHR mice in C57BL/6 background were 
generated by crossbreeding TetRE-CA-AHR mice with the FABP-tTA mice (88).  
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Figure 3. Generation of transgenic mice expressing CA-AHR in the liver and intestine. 
(A) Schematic representation of the Tet-off FABP-tTA/TRE-CA-AhR transgenic system. CMX, 
cytomegalovirus; DOX, doxycycline; FABP, fatty acid binding protein; PCMV, minimal CMV promoter; 
TRE, tetracycline responsive element; tTA, tetracycline transcriptional activator. (B) CV-1 cells in 48-
well plates were transiently transfected with pGud-Luc and TRE-CA-AHR together with expression 
vectors of tTA followed by DOX (1mg/mL) treatment for 24 hours before the luciferase reporter assay in 
triplicate groups. (C) Generation of TRE-CA-AHR transgenic mice. Shown are DNA gel (left) and 
integration and copy number of transgene (right) verified by Southern blot analysis of genomic DNA 
from mouse tails. Results are presented as means ± standard error of the mean (SEM). 
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Three founders were obtained and evaluated for the integration and copy numbers of the 
transgene as shown by Southern blot analysis (Fig. 3C). Crossbreeding of the TRE-CA-AHR 
founders with FABP-tTA mice yielded one bi-transgenic line, which was chosen for further 
characterization and most of the subsequent experiments. The liver-specific expression of CA-
AHR was confirmed at both mRNA and protein levels, without affecting the expression of 
endogenous AHR (Fig. 4A). The expression of typical AHR target genes was induced in TG 
livers, and abolished when mice were given DOX-contained drinking water for one week (Fig. 
4B). The gene regulatory effect appeared to be AHR specific and did not affect the activity of 
other partners of AHR nuclear translocator (ARNT), because the expression of VEGF, a typical 
target gene of the HIF1α-ARNT heterodimers, was not affected (Fig. 4C). 
Although AHR mediates most of the toxic and biological effects of TCDD, the ability of 
TCDD to produce effects in an AHR-independent manner has also been observed and likely 
contributes to the overall adverse effects of these compounds. Therefore, we checked the liver 
injury and inflammatory status in the AHR TG mice. Unlike the TCDD model of AHR activation, 
the transgene was not associated with obvious hepatotoxicity, because neither the serum levels of 
liver injury markers (ALT, AST, and ALP) (Fig. 5A) nor the expression of hepatic inflammatory 
cytokines or marker genes (Fig. 5B) were increased in the TG mice. 
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Figure 4. Characterization of the liver-specific expression of the CA-AHR. 
Wild-type (WT) and transgenic (TG) mice were 6 weeks old and maintained on chow diet. (A) The 
mRNA expression of the transgene in a panel of tissues (left) and Western blotting of hepatic wild type 
(WT) AHR and CA-AHR (right). (B) Hepatic mRNA expresssion of CA-AHR transgene and CYP1 
genes. DOX (1mg/ml) was given in drinking water for 2 weeks starting at 4-week old when necessary. (C) 
Hepatic mRNA expresssion of ARNT target gene VEGF. N=5 for each group. Results are presented as 
means ± standard error of the mean (SEM). 
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The TG mice showed apparent hepatomegaly. At 6 weeks, the liver accounted for 
4.38±0.23% of total body weight in WT mice, but 5.35±0.26% in TG mice with an increase of 
22% (Fig. 6A). Consistent with the previous study that transgenic mice overexpressing CA-
mAhr developed spontaneous steatosis at the age of 6 weeks old (49), lipid analysis in the CA-
AHR TG livers showed a significantly increased hepatic and cholesterol levels (Fig. 6B) as well 
as free fatty acid contents (Fig. 6C) as compared to WT livers. Oil-red O staining confirmed the 
lipid droplet accumulation in hepatocytes of TG mice (Fig. 6D).  
 
 
 
Figure 5. Activation of AHR in CA-AHR mice was not associated with obvious hepatotoxicity. 
Mice were 6 weeks old and maintained on chow diet. (A) Serum levels of ALT, AST, and ALP. (B) 
Hepatic mRNA expression of inflammatory cytokines and macrophage markers. N=5 for each group. 
Results are presented as means ± standard error of the mean (SEM). 
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Figure 6. CA-AHR TG mice developed spontaneous steatosis. 
Mice were 6 weeks old and maintained on chow diet. (A) The liver weight (LW) was measured as 
percentage of the total body weight (BW). (B) Hepatic triglyceride and cholesterol contents in liver 
homogenates were measured at 500 nm. (C) Hepatic free fatty acid (FFA) levels were measured using 
LC-MS method, and the data was presented as the summation of all FFA species. (D) Liver sections were 
stained with oil red o dye, and examined microscopically (400×). N=5 for each group. *, P<0.05; **, 
P<0.01, TG vs. WT. Results are presented as means ± standard error of the mean (SEM). 
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2.5.3 Activation of AHR Exacerbated High-Fat Diet (HFD)-Induced Steatosis 
To determine whether AHR played a role in diet-induced fatty liver and associated metabolic 
syndrome, we challenged TG mice with HFD. Upon HFD feeding, the TG livers were larger and 
appeared paler and fattier compared to the WT livers (Fig. 7A). Hepatic triglyceride and 
cholesterol contents were higher (Fig. 7B, left panel), whereas serum levels of triglyceride and 
cholesterol were lower in TG mice (Fig. 7B, right panel). Interestingly, HFD feeding alone 
resulted in the accumulation of small lipid droplets within the hepatocytes of WT mice, whereas 
AHR activation caused formation of large lipid droplets as shown by H&E and Oil-red O 
staining (Fig. 7C). Additionally, the small lipid droplets in WT liver were mainly localized in the 
central vein areas and were formed in almost all hepatocytes in that area, whereas the large lipid 
droplets in TG liver were mostly restricted to the portal vein areas and developed only in certain 
hepatocytes (Fig. 7C).  
Hepatosteatosis is a result of imbalanced triglyceride secretion, de novo lipogenesis, fatty 
acid oxidation, or fatty acid uptake (34). The secretion of VLDL, which indicates the capacity of 
triglyceride secretion, was inhibited in HFD-fed TG mice (Fig. 8A). The protein level of 
ApoB100, the main structural component of VLDL, was reduced in TG liver (Fig. 8B). 
Interestingly, the TG liver showed an unchanged rate of complete fatty acid (FA) oxidation (Fig. 
8C) and a decreased rate of incomplete FA oxidation (Fig. 8D), in which FAs entering the 
mitochondria are partially degraded and may generate toxic metabolites that contribute to insulin 
resistance. The expression of FA oxidation genes including Pparα and its targets Cpt1α, Lcad, 
and Mcad was decreased in TG liver (Fig. 8E), which was consistent with previous report in CA-
Ahr transgenic mice (49). Despite their exacerbated steatosis, the TG mice showed decreased 
expression of lipogenic genes, including Srebp1c, Acc1, Scd1, and Fas (Fig. 8E).  
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Figure 7. Activation of AHR exacerbated high-fat diet induced steatosis.  
(A to C) WT and AHR transgenic (TG) mice were fed with HFD for 12 weeks. Shown are the gross 
appearance of the livers (left) and liver weight (LW) to body weight (BW) ratio (right) at the end of HFD 
feeding (A); hepatic (left) and serum (right) triglyceride and cholesterol contents measured at 500 nm (B); 
H&E staining (left, 100× and 400×) and Oil-red O staining (right, 400×) of the liver sections (C), C 
indicates central vein, and P indicates portal vein. N=5 for each group. *, P<0.05; **, P<0.01, TG vs. WT. 
Results are presented as means ± standard error of the mean (SEM). 
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Figure 8. Decreased VLDL-triglyceride secretion and decreased fatty acid oxidation in TG mice. 
(A) Mice were fasted for 4 h before receiving an intravenous injection of tyloxapol, a lipoprotein lipase 
inhibitor at 500 mg/kg body weight. Tail vein blood samples were collected at 0, 60, and 90 min after the 
tyloxapol injection, and plasma triglyceride levels were measured at 500 nm. (B) Western blotting 
showing a decreased ApoB100 protein level in the serum of fasted TG mice, and ponceau red staining for 
internal control. (C) Complete fatty acid oxidation to CO2 and (D) incomplete fatty acid oxidation to acid 
soluble metabolites (ASM) in liver homogenates assessed by liquid scintillation counting of [14C]-CO2 
and [14C]-ASM, respectively. (E) mRNA expressions of lipid oxidation genes and lipogenic genes. N=5 
for each group. *, P<0.05; **, P<0.01, TG vs. WT. Results are presented as means ± standard error of the 
mean (SEM). 
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2.5.4 AHR Transgenic Mice Were Protected from Diet-induced Obesity and Insulin 
Resistance 
To our surprise, despite their exacerbated hepatosteatosis, the TG mice showed protection from 
diet-induced obesity and insulin resistance. Upon HFD feeding, the TG mice gained less body 
weight (Fig. 9A). At the end of the 12-week HFD feeding, TG mice were visibly leaner (Fig. 9B), 
and the lower body weight was accounted for largely by a reduction in the fat mass without 
affecting the lean mass (Fig. 9C). The difference in adiposity was not attributable to a reduction 
in food intake (Fig. 9D). The TG mice had lower fasting glucose  (Fig. 10A) and insulin levels 
(Fig. 10B), as well as improved performance in glucose tolerance test (GTT)  (Fig. 10C) and 
insulin tolerance test (ITT)  (Fig. 10D), suggesting insulin hypersensitivity in these mice. 
However, the tissue sensitivity to insulin could not be directly assessed by GTT or ITT, and a 
hyperinsulinemic-euglycemic clamp may be further needed (91). These phenotypes seen in diet-
induced mice were transgene dependent, because they were normalized in TG mice treated with 
DOX to silence the transgene expression (Fig. 13A-13C). 
2.5.5 The Pleotropic Effects of AHR in Improving Metabolic Function 
Although the AHR transgene was targeted to the liver, we observed metabolic benefits in 
multiple extrahepatic tissues, including adipose tissues and skeletal muscle. Obesity is associated 
with an increase in macrophage infiltration in adipose tissue (92). Consistent with their reduced 
size of visceral fat pad (Fig. 11A, left panel), the HFD-fed TG mice showed smaller adipocyte 
size and lower macrophage infiltration as shown by less crown-like structures (Fig. 11A, right 
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panel), which was supported by their decreased expression of macrophage marker genes F4/80 
and CD68 (Fig. 11B).  
 
 
Figure 9. AHR transgenic mice were protected from diet-induced obesity. 
WT and TG mice were fed with HFD for 12 weeks starting from 6 weeks old. (A) Body weights of mice 
during HFD challenge. (B) Appearance of WT and TG mice at the end of HFD feeding. (C) Body 
composition with fat and lean mass weights measured by EchoMRI. (D) Food intake measured between 
10- and 12-week of HFD feeding. N=5 for each group. **, P<0.01, TG vs. WT. Results are presented as 
means ± standard error of the mean (SEM). 
 
 
Reduction in fat mass without affecting food intake suggested an increase in energy 
expenditure. Indeed, both the oxygen consumption (Fig. 11C, left panel) and energy expenditure 
(Fig. 11C, right panel) were significantly higher in TG mice, which were normalized upon DOX 
treatment (Fig. 13D). There was also an increase in resting rectal temperature in TG mice (Fig. 
11D), another indicator of increased energy expenditure and thermogenesis. The brown adipose  
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Figure 10. AHR transgenic mice were protected from diet-induced insulin resistance. 
WT and TG mice were fed with HFD for 12 weeks starting from 6 weeks old. Mice were fasted overnight 
before measurements. (A) Fasting serum glucose levels were measured by the glucose meter. (B) Fasting 
serum insulin levels were measured by insulin-ELISA. (C to D) Glucose tolerance test (GTT) (C) and 
insulin tolerance test (ITT) (D) after overnight fasting. Area under curve (AUC) was calculated by the 
area between the curve and the x-axis. N=5 for each group. *, P<0.05; **, P<0.01, TG vs. WT. Results 
are presented as means ± standard error of the mean (SEM). 
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Figure 11. The pleotropic effects of AHR in improving metabolic function. 
WT and TG mice were fed with HFD for 12 weeks starting from 6 weeks old, and tissues were harvested 
at the end of HFD feeding. (A) Representative appearance (left) and H&E staining (right, 400×) of 
visceral fat tissues. Arrowheads indicate the crown-like structures, which are characteristic of macrophage 
infiltration. (B) White adipose tissue (WAT) expression of macrophage markers. (C) Measurements of 
oxygen consumption (left) and energy expenditure (right) using the Oxymax Indirect Calorimetry System. 
(D) Rectal tempeature measured by thermometer. (E) Representative appearance (left) and H&E staining 
(right, 400×) of brown fat tissue (BAT). (F) BAT expression of thermogenic markers. N=5 for each group. 
*, P<0.05; **, P<0.01, TG vs. WT. Results are presented as means ± standard error of the mean (SEM).  
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tissue (BAT) plays an important role in thermogenesis. The TG BAT was obviously browner 
(Fig. 11E, left panel), which was supported by smaller adipocytes with smaller lipid droplets (Fig. 
11E, right panel), and increased expression of BAT marker genes Dio2, Cidea and Elovl3 (Fig. 
11F).  
 
Figure 12. The pleotropic effects of AHR in improving metabolic function.  
WT and TG mice were fed with HFD for 12 weeks starting from 6 weeks old, and tissues were harvested 
at the end of HFD feeding. (A) Serum adiponectin level measured by adiponectin-ELISA, and adipose 
expression of adiponectin. (B) Western blotting of p-AMPKα and total AMPKα in liver, muscle, and 
WAT. (C) Complete fatty acid oxidation to CO2 in skeletal muscle homogenates (left) assessed by liquid 
scintillation counting of [14C]-CO2, and muscular expression of β-oxidation genes (right). N=5 for each 
group. *, P<0.05; **, P<0.01, TG vs. WT. Results are presented as means ± standard error of the mean 
(SEM). 
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We also observed an increased serum level and adipose expression of adiponectin (Fig. 
12A), an adipokine known to have anti-inflammatory activity and improve insulin sensitivity 
(93). AMP-activated protein kinase (AMPK) is a key player in regulating energy metabolism 
(94). We observed an elevated AMPKα phosphorylation/activation in the liver and skeletal 
muscle, but not the white adipose tissue (WAT), of TG mice (Fig. 12B), which was normalized 
upon DOX treatment (Fig. 13E). AMPK activation is known to promote fatty acid oxidation in 
the skeletal muscle (95). Indeed, the complete fatty acid oxidation rate in TG muscle was 
significantly increased (Fig. 12C, left panel), which was associated with an increased expression 
of Pgc1α, Cpt1α and Ucp3 (Fig. 12C, right panel). 
  
 37 
 
 
Figure 13. The metabolic benefits of the transgene were normalized upon DOX treatment. 
WT and TG mice were fed with HFD for 12 weeks starting from 6 weeks old, and DOX (1mg/ml) was 
given in drinking water starting from 6 weeks old. Tissues were harvested at the end of HFD feeding. 
Body, fat mass, and lean mass weights (A) and appearance of mice (B) at the end of HFD feeding. (C) 
Glucose tolerance test (GTT) (left) and insulin tolerance test (ITT) (right) performed at 10-week HFD 
feeding after overnight fasting. (D) Oxygen consumption (top) and energy expenditure (bottom) measred 
using the Oxymax Indirect Calorimetry System. (E) Western blotting of hepatic and muscular p-AMPKα 
and total AMPKα. N=5 for each group. Results are presented as means ± standard error of the mean 
(SEM). 
2.5.6 Activation of AHR Induced the Expression of FGF21 
The pronounced dissociation of hepatosteatosis from insulin resistance and the pleotropic 
metabolic benefits observed in our TG mice prompted us to examine the underlying mechanism. 
We found that both the hepatic mRNA (Fig. 14A) and protein expression (Fig. 14B) and 
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circulating concentration (Fig. 14C) of FGF21, a metabolic peptide hormone secreted 
predominantly by hepatocytes (96), were significantly increased in both the chow-fed and HFD-
fed TG mice. The FGF21 induction was liver-specific, because the induction was not seen in 
WAT and BAT (Fig. 14D). Both the serum level and hepatic expression of FGF21 in the TG 
mice were normalized upon DOX treatment (Fig. 15A, 15B, and 15C).  
 
 
 
Figure 14. Activation of AHR induced the expression of FGF21. 
Mice were fed with chow diet for 6 weeks, or HFD for 12 weeks starting at 6 weeks old. Tissues were 
harvested at the end of the HFD feeding. (A to C) Hepatic mRNA expression (A), Western blotting (B), 
and serum level (C) of FGF21 measured by FGF21-ELISA. (D) mRNA expression of FGF21 in tissues 
(liver, WAT, and BAT) of mice fed with HFD for 12 weeks. N=5 for each group. *, P<0.05; **, P<0.01, 
TG vs. WT. Results are presented as means ± standard error of the mean (SEM). 
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Figure 15. The AHR responsive induction of FGF21 was abolished upon DOX treatment. 
WT and TG mice were fed with HFD for 12 weeks starting from 6 weeks old, and DOX (1mg/ml) was 
given in drinking water starting from 6 weeks old. Tissues were harvested at the end of HFD feeding. (A 
to C) Serum level (A), hepatic mRNA expression (B), and Western blotting (C) of FGF21. N=5 for each 
group. Results are presented as means ± standard error of the mean (SEM). 
 
2.5.7 Knockdown of FGF21 Abolished the Metabolic Benefits of AHR 
To understand the functional relevance of FGF21 induction, WT and TG mice were fed with 
HFD for 6 weeks before receiving an intravenous injection of adenovirus expressing short 
hairpin RNA targeting FGF21 (Ad-shFGF21) or the control LacZ gene (Ad-shLacZ) (83). The 
FGF21 knockdown was validated at mRNA, protein and circulating levels (Fig. 16A, 16B, and 
16C). The lower body weight of TG mice was unchanged after FGF21 knockdown (Fig. 16D). 
We found that FGF21 knockdown abolished the transgenic effects in lowering fasting glucose 
levels (Fig. 16E) as well as improving glucose tolerance (Fig. 16F). 
Upon FGF21 knockdown, the extrahepatic benefits of the transgene were also abolished. 
These included the decreased WAT macrophage infiltration (Fig. 17A) and decreased WAT 
expression of pro-inflammatory cytokines and macrophage marker genes (Fig. 17B), browning 
of the BAT (Fig. 17C) and increased expression of BAT marker genes (Fig. 17D), and increased  
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Figure 16. Knockdown of FGF21 abolished the metabolic benefits of AHR. 
Mice were fed with HFD for 6 weeks before receiving intravenous injection of Ad-shFGF21 or Ad-
shLacZ at 5×109 viral particle/gram of body weight for 2 weeks. Tissues were harvested 2 weeks after the 
viral injection. Shown are hepatic mRNA expression (A), serum level (B), and Western blotting (C) of 
FGF21; body weight (D) and fasting serum glucose levels (E) 2 weeks after the viral injection; (F) 
glucose tolerance test (GTT) was performed 1 week after the viral injection, and area under curve (AUC) 
was calculated by the area between the curve and the x-axis. N=5 for each group. *, P<0.05; **, P<0.01, 
TG shLacZ vs. WT shLacZ, or the comparisons are labled. Results are presented as means ± standard 
error of the mean (SEM). 
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serum level of adiponectin (Fig. 17E). In the skeletal muscle, the increased complete fatty acid 
oxidation (Fig. 17F) and the elevated AMPKα phosphorylation (Fig. 17G) were attenuated upon 
FGF21 knockdown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Knockdown of FGF21 abolished the metabolic benefits of AHR in extrahepatic tissues. 
Mice were fed with HFD for 6 weeks before receiving intravenous injection of Ad-shFGF21 or Ad-
shLacZ at 5×109 viral particle/gram of body weight for 2 weeks. Tissues were harvested 2 weeks after the 
viral injection. (A and B) H&E staining (400×) (A) and expression of inflammatory marker genes (B) in 
WAT. Arrowheads indicate the crown-like structures. (C and D) H&E staining (400×) (C) and expression 
of thermogenic markers (D) in BAT. (E) Serum adiponectin levels measured by adiponectin-ELISA. (F) 
Complete fatty acid oxidation to CO2 in skeletal muscle homogenates assessed by liquid scintillation 
counting of [14C]-CO2. (G) Western blotting of hepatic and muscular p-AMPKα and total AMPKα levels. 
N=5 for each group. *, P<0.05; **, P<0.01. Results are presented as means ± standard error of the mean 
(SEM). 
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2.5.8 FGF21 Knockdown Ameliorated Hepatosteatosis by AHR Activation 
Interestingly, the large lipid droplets in HFD-fed TG livers were depleted upon FGF21 
knockdown (Fig. 18A, left panel). FGF21 knockdown did not alter the repressed VLDL secretion 
in TG mice (Fig. 18A, right panel). The elevated hepatic triglyceride and cholesterol contents  
 
 
 
Figure 18. FGF21 knockdown ameliorated hepatosteatosis by AHR activation. 
Mice were fed with HFD for 6 weeks before receiving intravenous injection of Ad-shFGF21 or Ad-
shLacZ at 5×109 viral particle/gram of body weight for 2 weeks. Tissues were harvested 2 weeks after the 
viral injection. (A) H&E staining of liver tissues (left, 400×) and VLDL-triglyceride secretion rate 
measured by serum triglyceride levels at 500 nm at 0, 60, and 90 min after tyloxapol injection (right). (B) 
Hepatic (left) and serum (right) triglyceride and cholesterol contents. (C) Hepatic mRNA expression of 
lipid droplet associated genes. (D) Hepatic free fatty acid (FFA) contents measured by LC-MS method 
(left), complete hepatic fatty acid oxidation to CO2 (middle), and incomplete hepatic fatty acid oxidation 
to acid soluble metabolites (ASM) (right) assessed by liquid scintillation counting of [14C]-CO2 and [14C]-
ASM, respectively. N=5 for each group. *, P<0.05; **, P<0.01, TG shLacZ vs. WT shLacZ, or the 
comparisons are labled. Results are presented as means ± standard error of the mean (SEM).  
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were decreased after FGF21 knockdown (Fig. 18B), which was associated with increased serum 
levels of triglycerides and cholesterol (Fig. 18B). Consistent with the decreased lipd droplet size, 
the induction of several lipid droplet-associated genes observed in shLacZ-infected TG mice, 
including Plin1, Plin3, and Cidec, was decreased in shFGF21-infected TG mice (Fig. 18C). The 
hepatic FFA concentrations (Fig. 18D, left panel) and fatty acid oxidation rate (Fig. 18D, right 
panel) in TG mice were not affected by FGF21 knockdown. 
2.5.9 FGF21 Knockdown Exacerbated Liver Damage in CA-AHR Mice 
Paradoxically, the depleted lipid droplets in shFGF21-infected TG livers was associated with 
hepatotoxicity as supported by increased hepatocyte degeneration and lymphocyte infiltration 
(Fig. 18A, left panel), increased expression of pro-inflammatory genes (Fig. 19A), increased 
serum IL-6 level (Fig. 19B), and increased serum ALT level (Fig. 19C). The hepatic 
concentrations of lipid intermediates diacylglycerol and ceramide, both of which are known to be 
lipotoxic (97, 98), were not affected in TG mice (data not shown).  
 
Figure 19. FGF21 knockdown exacerbated liver damage in CA-AHR mice.   
Mice were fed with HFD for 6 weeks before receiving intravenous injection of Ad-shFGF21 or Ad-
shLacZ at 5×109 viral particle/gram of body weight for 2 weeks. Tissues were harvested 2 weeks after the 
viral injection. (A) Hepatic mRNA expression of pro-inflammatory cytokines. (B) Serum level of IL-6 
measured by IL-6-ELISA. (C) Serum ALT level. N=5 for each group. *, P<0.05. Results are presented as 
means ± standard error of the mean (SEM). 
 44 
2.5.10 FGF21 is a Direct Transcriptional Target of AHR 
The induction of FGF21 was also observed in WT mice acutely treated with TCDD, and this 
induction was abolished in AHRKO mice (Fig. 20A). These results, together with the FGF21 
induction in TG mice, strongly suggested FGF21 as an AHR target gene. To directly test whether 
FGF21 is an AHR target gene, we cloned the human and mouse FGF21 gene promoters and 
evaluated their regulation by AHR. Inspection of the promoters revealed two putative dioxin 
responsive elements (DREs) in the hFGF21 gene promoter and one DRE in the mFGF21 gene 
promoter, whose bindings to the AHR-ARNT heterodimers or the CA-AHR-ARNT heterodimers 
were confirmed by EMSA (Fig. 20B). To confirm the recruitment of CA-AHR onto the hFGF21 
gene promoter in vivo, we performed ChIP assay on cells transfected with Flag-CA-AHR. As 
shown in Fig. 20C, CA-AHR specifically recruited to the two DRE-franking regions, but not the 
control non-DRE region. The in vivo recruitment of CA-AHR onto the mFGF21 gene promoter 
was confirmed by ChIP assay in WT mice whose livers were hydrodynamically transfected with 
Flag-CA-AHR (Fig. 20D). The transactivation of the FGF21 gene promoters by AHR was 
evaluated by luciferase reporter gene assays. As shown in Fig. 20E, the 2-kb hFGF21 gene 
promoter was transactivated by CA-AHR or AHR in the presence of the AHR agonist 3-MC, 
whereas this activation was abolished when the region containing both DREs was deleted. A 
similar pattern of results was obtained when the mFGF21 gene promoter was evaluated (Fig. 
20F).  
  
 45 
 
  
 46 
Figure 20. FGF21 is a direct transcriptional target of AHR. 
(A) Eight-week old WT and AHR knockout (AHRKO) mice were treated with a single dose of TCDD (30 
μg/kg) and sacrificed 4 h later. The hepatic mRNA expression of CYP1B1 and FGF21. (B) The sequences 
of human and mouse FGF21 DREs and their mutant variants (top) and EMSA results (bottom). (C and D) 
ChIP assay in triplicate groups to show the recruitment of CA-AHR onto the human (C) and mouse (D) 
FGF21 promoters. 293 cells were transfected with pCMX-Flag-CA-AHR in (C) and WT mouse livers 
(N=5 for each group) were hydrodynamically transfected with pCMX-Flag-CA-AHR in (D). (E and F) 
Activation of the human (E) and mouse (F) FGF21 promoter reporter genes by AHR in the presence of 3-
methylcholanthrene (3-MC), or by CA-AHR without an exogenously added ligand. HepG2 cells were co-
transfected with indicated reporters and receptors. Transfected cells were treated with vehicle DMSO or 
3-MC (4 μM) for 24 h before luciferase assay in triplicate groups. *, P<0.05; **, P<0.01. Results are 
presented as means ± standard error of the mean (SEM). 
 
2.6 DISCUSSION 
One of our most interesting findings in this study is the revelation of the AHR-FGF21 pathway 
and the implication of this regulation in conferring the metabolic benefit of AHR activation. 
FGF21, a peptide hormone and a potential therapeutic agent for diabetes, is known to have 
multiple metabolic benefits including reducing body weight and improving insulin sensitivity 
(85). We showed the induction of FGF21 was transgene specific, because silencing of the 
transgene normalized the induction and attenuated the metabolic benefit. We also showed, 
through the FGF21 knockdown, that FGF21 was required for the metabolic benefit of the 
transgene. The increased circulating level of FGF21 may have contributed to the pleotropic and 
extrahepatic benefits of the liver-specific AHR activation, such as those observed in the adipose 
tissues and skeletal muscle. The increased adipose expression and circulating level of 
adiponectin in TG mice were consistent with the notion that adiponectin mediates the systemic 
effects of FGF21 on energy metabolism and insulin sensitivity in skeletal muscle (87). The 
AMPKα phosphorylation in the liver and skeletal muscle of TG mice was increased, consistent 
with the report that FGF21 regulates energy homeostasis through the activation of AMPK (99). 
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Although FGF21 expression can be regulated by PPARα (83, 84), the hepatic expression of 
PPARα and its downstream target genes was down-regulated in TG mice, suggesting that 
PPARα was unlikely the mediator for the FGF21 induction in our mice. 
Another intriguing finding is the dissociation between hepatosteatosis and insulin 
resistance in our TG mice. Although paradoxically, several recent studies suggested that 
hepatosteatosis and insulin resistance can be dissociated. In one such example, liver-specific 
knockout of the histone deacetylase 3 improved insulin sensitivity despite the hepatosteatosis 
(100). In another example, overexpressing the acyl-CoA:diacylglycerol acyltransferase 2 in the 
liver increased lipid accumulation without developing insulin resistance (101). One possibility 
that accounts for the dissociation is that insulin resistance may reflect inflammation rather than 
lipid accumulation in the liver (102). Indeed, there was no sign of increased inflammation in the 
TG liver, despite elevated triglyceride and cholesterol levels and FFA contents, suggesting that 
these lipids are sequestered in lipid droplets and thus prevented from causing lipotoxicity. In 
contrast, knockdown of FGF21 may have resulted in rupture of lipid droplets, leading to liver 
inflammation and toxicity, as well as the masking of insulin hypersensitivity. Our results 
suggested that in the context of AHR activation, FGF21 may have promoted lipid sequestration 
and storage into lipid droplets by up-regulating the expression of lipid droplet-associated genes 
(Fig. 18C), the mechanism of which remains to be understood. Decreased hepatic lipid contents 
were accompanied by increased serum triglyceride and cholesterol levels in FGF21-depleted TG 
mice, suggesting that liver fat is redistributed to the periphery.  
The lack of increased hepatic fatty acid oxidation in HFD-fed TG mice seemed 
contradictory to the known function of FGF21 in promoting fatty acid oxidation and 
tricarboxylic acid cycle flux in the liver (103, 104). However, our TG mice also showed 
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decreased expression of PPARα and other fatty acid oxidation genes, which was consistent with 
those observed in transgenic mice expressing the constitutively activated mouse Ahr (49). The 
mechanism by which AHR supresses faty acid oxidation is unclear. Nevertheless, we reasoned 
the decreased incomplete oxidation and unchanged complete oxidation were the net result of the 
opposing effect of FGF21 and AHR on fatty acid oxidation. The absence of change in hepatic 
fatty acid oxidation after FGF21 knockdown also suggested a limited effect of FGF21 on hepatic 
fatty acid oxidaiton in our TG mice.  
AHR was initially defined as a xenobiotic receptor that regulates drug metabolism. 
Subsequent observations, such as the developmental defects in AHR null mice (18, 105) and 
identification of endogenous AHR ligands (28, 106) have suggested equally important endobiotic 
functions of AHR. More recent studies suggested AHR also plays many other essential 
biological functions, such as functioning as an E3 ligase (107) and affecting the expansion of 
human hematopoietic stem cells (108). The typical pharmacological model of AHR activation 
using TCDD is often associated with toxicity that may affect the data interpretation, especially 
when the ligand has to be used chronically. Our TG mice offers a unique gain of function model 
to understand the endobiotic function of AHR without the concern of the toxicity. 
Our findings that activation of AHR protected mice from diet-induced obesity and insulin 
resistance seems contradictory to the other two reports that AHR-null mice displayed enhanced 
insulin sensitivity and improved glucose tolerance in both normal chow diet- and high fat diet-
fed conditions (65, 66). However, one explanation for this discrepancy is that the lack of AHR 
expression may not be equal to repression of AHR activity. In addition, the disadvantage of 
using genetic models is the likelihood of causing developmental issues, which may affect the 
metabolic function as well. Further studies using either AHR agonists or antagonists will better 
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evaluate the metabolic function of AHR in vivo.  
FGF21 was demonstrated as a key regulator in the body’s adaptation to fasting 
downstream of PPARα regulation (83, 84). However, fasting-induced FGF21 expression was 
unchanged in the AHR null mice (data not shown), indicating that the PPARα-FGF21 axis 
remains intact in the absence of AHR. Rather than physiological changes such as fasting, our 
study suggests that the AHR-FGF21 pathway is more responsive to exogenous insults. There are 
varied exogenous AHR ligands persistent in our environment with TCDD being the most potent. 
In our current study, TCDD is able to induce the expression of FGF21 in an AHR-dependent 
manor. Moreover, TCDD treatment in mice reproduced hepatic steatosis (49) and peripheral 
metabolic phenotype (109) as observed in our CA-AHR transgenic mice, revealing the 
consistency of the pharmacological and genetic manipulations. Furthermore, FGF21 was 
reported to be up-regulated during acute liver injury by exposure to acetaminophen (110) and/or 
chronic liver injury by HFD feeding (111), although it is unknown yet whether AHR is 
indispensable for FGF21 induction in these pathological models.  
In summary, we showed that transgenic activation of AHR in the liver alleviated mice 
from HFD-induced obesity and insulin resistance despite having marked hepatosteatosis. The 
dissociation between fatty liver and insulin resistance likley has been mediated by the AHR-
dependent activation of FGF21. We propose the endocrine hormone FGF21 as an important 
effector for the endobiotic function of AHR in lipid metabolism and energy homeostasis. Our 
results also argue that development of non-toxic AHR agonists may be a novel approach in 
managing metabolic syndrome.  
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3.0  CHAPTER III: FUNCTION OF AHR IN PROMOTING HEPATIC 
CARCINOGENESIS 
3.1 THE ROLE OF AHR IN HEPATIC CARCINOGENESIS 
3.1.1 AHR in Liver Carcinogenesis 
TCDD is considered as both a complete epigenetic carcinogen and a potent tumor promoter (12). 
Rather than a genotoxic carcinogen, TCDD has proven to be particularly effective during the 
promotional stage of carcinogenesis in the two-stage initiation-promotion model (112). It is 
believed that although the binding of AHR by TCDD may not be sufficient for its 
carcinogenicity, it is necessary for its action.  The effects of TCDD on liver carcinogenesis in 
rodents have been the focus for many years, in which a genotoxic carcinogen diethylnitrosamine 
(DEN) was applied to initiate genetic alterations followed by TCDD exposure. Using genetic 
murine models that express various AHR alleles, AHR has been suggested to play a key role in 
TCDD-induced liver tumor promotion. For example, mice that encode a receptor with low 
binding affinity for TCDD (Ahrd) showed dramatically decreased liver tumor formation 
compared to mice with high binding affinity (Ahrb) when exposed to both the initiation event 
(DEN) and the promotion event (TCDD) (113). Additionally, in mice expressing constitutively 
activated Ahr (CA-Ahr), the liver tumor prevalence and multiplicity were much higher than that 
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in wild-type mice after DEN exposure (114). However, generation of AHR deficient mice has 
shown increased tumor formation in DEN-initiated HCC model (no TCDD exposure), suggesting 
a tumor suppressing effect by AHR (115). This discrepancy might be explained by the fact that 
the lack of AHR expression may not be equated with repression of AHR activity, such as during 
the treatment of an existing tumor with an AHR antagonist (12). These observations would 
support testing whether TCDD can persistently promote liver tumor in AHR-null mice using the 
two-stage model. Overall, these findings support the conclusion that AHR activation enhances 
liver tumor formation and thus, antagonism of AHR activity by exogenous or endogenous AHR 
antagonists would be a logical way to consider AHR as a therapeutic target. 
Inflammatory signaling was recently recognized as a major player in the mechanisms of 
liver tumor promotion (116). Particularly, absence of the receptors for TNFα/β and IL-1α a/β 
conferred resistance to the tumor promoting effects of TCDD characterized by much less number 
and size of liver tumors, suggesting that similar to the mechanisms of TCDD-induced acute 
hepatotoxicity, inflammatory signaling plays an important role in TCDD-induced liver tumor 
promotion in mice (113).  
AHR may possess intrinsic functions in regulating cell cycle that are independent of its 
ligands. The cell cycle consists of five phases: G0, G1, S, G2, and M. Earlier studies showed that 
AHR-defective Hepa1c1c7 cells displayed a prolonged doubling time compared with wild-type 
cells, which was due to delayed progress into G1 phase (117). Knockdown of AHR in human 
HepG2 cells resulted in growth inhibition as well as decreased expression of cell cycle–related 
genes including cyclins D1 and E, cdk2, and cdk4 (118).  On the other hand, AHR ligand 
treatment by TCDD was also shown to promote metastasis and cell migration through inducing 
metastasis marker anterior gradient 2 (AGR2) (119) and activating non-genomic focal adhesion 
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kinase (FAK)/Src pathway (120) in an AHR-dependent manner. However, TCDD was also 
reported to cause cell cycle arrest due to the crosstalk between AHR and the retinoblastoma (Rb) 
protein (121). Rb is a cell cycle-related phosphoprotein that complexes with E2F protein to 
repress E2F responsive genes, thereby inhibiting cell cycle entry from G1 into S phase. The 
direct AHR-Rb interaction was reported by both the yeast two-hybrid system and co-
immunoprecipitation assays, and it participated in the transcriptional repression of the E2F- 
induced cell cycle progression (121-123). 
The effect of AHR activation in HCC has also been linked through inhibiting apoptosis. 
In studies of the two-stage liver tumor promotion model, TCDD was shown to mediate clonal 
expansion of “initiated” preneoplastic hepatocytes by inhibiting apoptosis and bypassing AHR-
mediated growth arrest (124). But other contradictory results indicated that TCDD induced 
apoptosis (125), which might be due to AHR-mediated oxidative stress generated by P450 
enzyme induction (54). AHR-mediated metabolic conversion of its agonist BaP (a constituent of 
cigarette smoke) to the ultimate carcinogen benzo[α]pyrene-7,8-diol-9,10-epoxide (BPDE) lead 
to DNA adducts formation and mutagenesis. And the carcinogenic effects of BaP were AHR-
dependent by the observation that the tumor formation was lost in mice lacking AHR (126) or 
decreased in mice lacking CYP1B1 (127). However, BPDE was also shown to induce apoptosis 
in HepG2 cells, which might be linked to the induction of the p38 MAPK (128).  
3.1.2 Species Difference of AHR in Promoting Hepatic Carcinogenesis 
The International Agency for Research on Cancer (IARC) has classified TCDD as a “ 
Group I human carcinogen” (72), based on the carcinogenic effect of TCDD on experimental 
animals. However, this definition has been controversial for a long time due to insufficient and 
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inconsistent evidence of carcinogenicity in humans (129). In several follow-up epidemiologic 
studies on TCDD-exposed populations, the association between the increase of the total cancer 
incidence and TCDD exposure was much weaker and should be considered as inadequate rather 
than limited evidence of its carcinogenicity (129). And moreover, these studies were carried out 
by the same group and have not been confirmed by other investigators. This large inter-species 
variation severely limits generalizations from animals to humans.  
Of note, there are marked species differences in the ligand-dependent activation of AHR, 
which is attributed to the sequence divergence in their ligand-binding domains. The human AHR 
has a 10-fold lower affinity for TCDD compared with the Ahrb, which results in a much lower 
toxicity in human associated with TCDD exposure (130). Sequence analysis revealed a critical 
alteration in the ligand binding domain that is responsible for the variation in TCDD response 
between human and mouse: V381 in the hAHR versus A375 in the mAhrb (130). Moreover, 
there is only 58% similarity in the AHR C-terminal transactivation domain between human and 
mouse, suggesting that AHR may regulate a distinct subset of genes in response to activation 
(131). DNA microarray analysis of TCDD-treated hepatocytes from WT C57BL6/J mice and 
humanized AHR C57BL6/J mice showed dramatic species differences in AHR-regulated gene 
induction and repression (132). This structural difference underlines the importance of using 
humanized AHR transgenic mice to address the species specificity of AHR responses in vivo. 
DEN treatment on transgenic mice expressing CA-Ahr clearly demonstrated the 
oncogenic potential of the activated mouse Ahr in promoting hepatic carcinogenesis (114). Since 
the animal evidence relating TCDD exposure to hepatic carcinogenesis is much stronger than 
that for humans, we do not know whether activation of human AHR itself is sufficient in 
 54 
promoting hepatic carcinogenesis. Therefore, our research goal is to explore the function and 
molecular mechanisms of human AHR in the liver tumor promoting effect.  
 
3.2 SPECIFIC AIMS 
Having known that TCDD is a potent liver tumor promoter in mice, but it is not sufficient to 
activate the human AHR due to the species difference in their ligand binding affinity, we want to 
explore the role of human AHR in hepatic carcinogenesis. Gain-of function of mouse Ahr in CA-
Ahr transgenic mice showed significantly more liver tumor formation, suggesting that genetic 
activation of mouse Ahr is also sufficient in promoting hepatic carcinogenesis. Therefore, our 
interest is to study whether and how genetic activation of human AHR plays a role in hepatic 
carcinogenesis using our CA-AHR transgenic mouse model.  
Aim 1: To determine the tumor promoting effects of human AHR in the two-stage 
hepatic carcinogenic model using humanized CA-AHR transgenic mice. 
Aim 2: To compare the tumor promoting effect between mouse and human AHR in 
hepatic carcinogenesis.  
Aim 3: To explore the potential mechanisms underlying the tumor promoting effect 
by AHR activation. 
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3.3 METHODS 
Mice  
The generation of CA-AHR and CA-Ahr transgenic mice has been described in chapter 1 as well 
as in previous reports (49, 133). Two-stage liver tumor model will be established in both CA-
AHR and CA-Ahr mice for a direct comparison. To generate the homozygous Gadd45b (growth 
arrest and DNA-damage-inducible beta)-/- (GK) mice that harbor a null allele for Gadd45b, 
Gadd45+/- mice in C57BL/6J background (stock number: 013101) from the Jackson Laboratory 
(Bar Harbor, ME) were self-crossed. Genotyping was performed by PCR using primers (10936: 
GCAACCCCAGTAACTTTGGA; 10937: CCTGCAGGAGAGAAGGAGTG; oIMR7996: CTT 
CCATTTGTCACGTCCTG) provided by the Jackson Laboratory. The complete deletion of 
Gadd45b was confirmed at the mRNA level by RT-PCR on RNA extracted from adult liver 
tissues. CA-AHR transgenic mice were crossbred with Gadd45b-/- mice to generate the CA-
AHR/Gadd45b-/- (AGK) mice in C57BL/6J background, and to study the requirement of 
Gadd45b in the tumor promoting effect of AHR. AHR knockout (AHRKO) mice in C57BL/6 
background were purchased from Taconic (Hudson, NY) to study the requirement of AHR in 
TCDD-induced Gadd45b transcription. WT male mice in CD-1 background were purchased 
from Charles River Laboratories for hydrodynamic overexpression of Gadd45b in the 
coactivation experiment.  
 
Mice Treatment 
In the two-stage initiation-promotion liver tumor model, 6-week-old male and female littermates 
from WT, CA-AHR, CA-Ahr, GK, and AGK mice (N=6-11 for each group) were injected 
intraperitoneally with a single dose of 90 μg/kg of body weight of DEN dissolved in saline and 
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sacrificed at 9 months after DEN injection. An equal volume of saline was injected to littermates 
as controls. For the gene regulation analysis, 10-week-old male C57BL/6J WT, AHRKO, and 
GK mice were treated by gavage with a dose of 10 μg/kg body weight of TCDD or 10 ml/kg 
body weight of corn oil once a day for 4 days before sacrifice. For hydrodynamic gene delivery 
study, 10-week-old male CD-1 WT mice were treated by a single gavage of 10 μg/kg body 
weight of TCDD or 10 ml/kg body weight of corn oil 7 days before the hydrodynamic 
transfection of pCMX-Flag-Gadd45b or pCMX-Flag empty construct into mouse livers.  
 
Histology and immunohistochemistry 
For H&E staining, liver tissues that bear tumors were fixed in 10% buffered formalin, embedded 
in paraffin, sectioned at 4 μm, and stained with hematoxylin and eosin. To detect Ki67 and 
Gadd45b proteins by immunohistochemistry, consecutive sections were deparaffinized and 
rehydrated.  For antigen retrieval, tissue sections were immersed in the 10 mM citrate buffer (PH 
6.0) at a sub-boiling temperature for 10 min followed by the treatment with 0.3% hydrogen 
peroxide for 30 min to inactive the endogenous peroxidase. To block the non-specific signal, 
sections were incubated with goat serum (1:200) at room temperature for 1 h, followed by 
incubation with the primary antibodies against Ki67 (1:200, ab15580, Abcam) or Gadd45b 
(1:200, ab197990, Abcam) at 4°C for overnight. Slides were then washed and incubated with a 
1:200 diluted biotinylated anti-rabbit antibody at room temperature for 30 min. After incubation 
with the avidin-biotin-horseradish peroxidase complex (Vectastain ABC Peroxidase kit, Vector 
Laboratories) at room temperature for 30 min, slides were incubated with freshly prepared DAB 
substrate for 3-5 seconds and slightly counterstained with hematoxylin.  
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Serum Biochemical Analysis 
Serum ALT and AST levels were measured by using commercial assay kits (Stanbio Laboratory, 
Boerne, TX).  
 
Co-immunoprecipitation and Western Blotting Analysis 
To study the interaction between AHR and Gadd45b proteins, 293T cells in 6-well plate were co-
transfected with pCMX-HA-AHR and pCMX-Flag-Gadd45b plasmids, and treated with 3-MC 
for 24 hours. Cells were lysed in the NP-40 lysis buffer supplemented with proteinase inhibitors 
(1:200) and incubated with antibodies against HA-tag at 4°C for overnight, followed by 
incubation with protein G agarose beads at 4°C for 1 hour. Cells were then washed with the NP-
40 lysis buffer and subjected to western blot analysis. Protein samples were resolved by SDS-
PAGE gel, transferred to a polyvinylidene fluoride membrane, and blotted with antibodies. The 
primary antibodies used include those against HA-tag (cat# 26183, Pierce), Flag-tag (cat# F7425, 
Sigma), VP16 (cat# sc-7545, Santa Cruz), and Gal4-DBD (cat# sc-510, Santa Cruz).  
 
Electrophoretic Mobility Shift Assay (EMSA), Chromatin Immunoprecipitation (ChIP) 
Assay, Transient Transfection and Luciferase Reporter Assay 
EMSA was performed using 32P-labeled oligonucleotides and receptor proteins prepared by the 
TNT method (88). ChIP assay for the Gadd45b promoter was performed in WT CD-1 mice (N=4 
for each group) whose livers were transfected with the pCMX-Flag-CA-AHR plasmid or pCMX-
Flag empty vector by a hydrodynamic gene delivery method for 8 h (88). Cells or liver lysates 
were immunoprecipitated with the anti-Flag or Anti-IgG antibody (Sigma) (88). The recovered 
DNA was assayed for enrichment of the Gadd45b promoter (-1286~ -1277) by RT-PCR. For 
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luciferase reporter assay, the Gadd45b reporter plasmids (-1332/+1, -1263/+1) were PCR-
amplified. CV1 cells in triplicate groups were transfected with the reporter construct together 
with the AHR or CA-AHR expression vector in 48-well plates. For the coactivation analysis, 
Huh7 cells in triplicate groups in 48-well plates were transfected with pCMX-Flag-Gadd45b (50, 
100, and 200 ng/well) and pCMX-AHR (50 ng/well) constructs, together with the pGud-reporter 
gene. When necessary, cells were treated with 3-MC (4 μM) for 24 h before luciferase assay. The 
transfection efficiency was normalized against the β-galactosidase activities from a co-
transfected CMX-β-galactosidase vector. 
 
Mammalian two-hybrid analysis 
To access the direct AHR-Gadd45b interaction in vivo, fusion constructs containing the Gal4 
DNA-binding domain (DBD) upstream of full-length or mutant Gadd45b (1-160, 1-125, 1-92, 
93-160, and 126-160) (134), and the fusion vector containing the herpes simplex virus VP16 
activation domain downstream of full-length Ahr were co-transfected into 293T cells in 48-well 
plates, along with a thymidine kinase luciferase reporter containing the Gal4 binding site (Tk-
UAS (upstream activating sequence)). The pCMX-Gal4 and pCMX-VP empty plasmids were 
used as controls. The luciferase reporter activity of Tk-UAS in triplicate groups was normalized 
against the β-galactosidase activities from a co-transfected CMX-β-galactosidase vector. 
 
Quantitative RT-PCR 
Total RNA was extracted using TRIzol and subjected to reverse transcription with random 
hexamer primers and Superscript RT III enzyme (Invitrogen). SYBR Green-based qRT-PCR was 
performed with the ABI7500 System. Data were normalized against the cyclophilin control.  
 59 
 
Statistical Analysis 
When applicable, results are presented as means ± standard error of the mean (SEM). Statistical 
significance between the means of two groups was analyzed using an unpaired Student t test, and 
analysis of variance (ANOVA) for the comparison among the means of three or more groups. 
Differences were considered statistically significant at P < 0.05. 
3.4 RESULTS 
3.4.1 Activation of Human AHR Promoted DEN-initiated Liver Tumor  
 
Figure 21. Schematic representation of the two-stage initiation-promotion liver tumor model.  
In the two-stage model, a chemical carcinogen or UV irradiation acts as a tumor initiator, which causes 
genetic alterations such as DNA damage and mutagenesis. The clonal expansion and tumor progression 
require a tumor promoter such as UV irradiation and tumor promoter.  
 
To study the human relevance of AHR in promoting liver tumors, we analyzed the susceptibility 
of mice expressing CA-AHR to DEN-initiated liver tumor development in the “Two-stage 
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initialization-promotion” model. Multistage carcinogenesis can be divided into three stages, 
termed initiation, promotion and progression (Fig. 21). Both genotoxic and non-genotoxic 
mechanisms contribute to the tumor development. Genotoxic events, including activation of 
oncogenes and/or loss of tumor suppressor genes, are the foundations of carcinogens. It can be  
induced by either endogenous or exogenous stimulus, such as DEN, which is a chemical 
carcinogen that induces the initiation of tumor cells through irreversible genetic alterations. The 
“initiated” cells may either be removed by apoptosis or be selected for expansion by a non-
genotoxic stimulus, which may involve a variety of mechanisms including stimulation of  
regenerative cells by hormone-mediated growth stimulation or by actions of liver tumor 
promoters, such as phenobarbital- and dioxin-like chemicals (124).  
Table 1. Liver tumors in DEN-treated male and female WT, CA-Ahr, and CA-AHR mice. 
Gender Genotype LW/BW (%) Number 
Tumor 
incidence 
(%) 
Multiplicity 
1-3mm 3-7mm >8mm 
Male 
WT 4.09±0.66 11 0 (0%) 0 (0) 0 (0) 0 (0) 
CA-Ahr 6.58±3.03* 9 8 (89%) 6.1 (55) 2 (18) 0.7 (6) 
CA-AHR 5.36±1.13** 10 10 (100%) 3.2 (32) 2.9 (29) 0.3 (3) 
Female 
WT 4.10±0.24 11 0 (0%) 0 (0) 0 (0) 0 (0) 
CA-Ahr 4.93±0.83** 6 2 (33%) 2 (12) 0.3 (2) 0.2 (1) 
CA-AHR 5.23±0.70** 10 3 (33%) 0.4 (4) 0.3 (3) 0.1 (1) 
Livers were harvested 9 months after DEN exposure, and tumors on the liver surface were counted. 
Results are presented as means ± standard error of the mean (SEM). The number of mice in each group 
are shown in the table. The tumor incidence (%) repreesnts the ratio of the number of mice with tumors 
to the total number of mice in each group. The tumor multiplicity was calculated from the total tumor 
countings (denoted in the brakets) with varying tumor sizes divided by the total mouse numbers in each 
group. *, P<0.05; **, P<0.01. CA-Ahr vs. WT or CA-AHR vs. WT.  
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To directly compare the efficiency between human AHR and mouse Ahr in promoting 
hepatic carcinogenesis, two groups of CA-AHR and CA-Ahr transgenic mice in both genders 
were analyzed in this two-stage model. Wild-type age-matched littermates were included as 
controls. At the end of the experiment, the liver to body weight ratio in male CA-AHR and CA-
Ahr mice were 5.36±1.13 and 6.06±1.81, respectively, compared to 4.09±0.66 in male WT mice 
(Table 1). There was 0% tumor in male WT mice and their livers look relatively normal (Fig. 22). 
Consistent with the previous study (114), the whole-body CA-Ahr transgenic male mice 
developed significantly enhanced liver tumors, as indicated by 89% of tumor incidence as well 
as increased tumor multiplicity and nodule size (Table 1). Surprisingly, we found that activation 
of human AHR also substantially promoted liver tumor, characterized by 100% of tumor 
incidence and enhanced nodule multiplicity and size (Table 1). Gross appearance showed one or 
multiple tumors on the surface of the CA-AHR mice livers, with the largest nodule more than 
10mm in diameter (Table 1, Fig. 20). This observation suggested that direct activation of human 
AHR works at least as efficiently as mouse Ahr in promoting liver tumor formation in male mice.  
Females are known to have much lower liver cancer risks, which is in agreement with the 
DEN-induced mouse liver tumor (116). Indeed, the female mice developed much lower tumor 
incidence (33% in both CA-AHR and CA-Ahr mice) and multiplicity. The liver weight to body 
weight ratio in female CA-AHR and CA-Ahr mice were 5.23±0.70 and 4.93±0.83, respectively, 
compared to 4.10±0.24 in WT mice. Among those mice with no tumors, hepatic cysts were 
commonly found on the liver surface (data not shown). In the following experiments, we mainly 
focused on studying the liver promoting effect of human AHR in male mice. 
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Figure 22. Representative gross tumor appearance of DEN-treated mice after 9 months.  
Mice were i.p. injected with a single dose of 90 μg/kg DEN at 6-week-old. Shown are the representative 
images of the gross appearances of mice livers at 9 months after DEN challenge. N=6-11 for each group.  
 
 
The tumors promoted by AHR activation were further analyzed under the microscope by 
H&E staining. Histologically, the liver architecture became trabecular and solid in both the CA-
AHR and CA-Ahr mice, whereas WT mice displayed normal liver structure (Fig. 23A). Within 
the nodule area, hepatocytes displayed obvious degeneration and atypia, including enlarged and 
hyperchromatic nuclei, prominent nucleoli, and mitosis (indicated by arrows) (Fig. 23B), which 
are characteristic for hepatic carcinogenesis. The protein expression of Ki67 is strictly associated 
with cell proliferation, and the fraction of Ki67-positive tumor cells (the Ki67-labeling index) is 
often correlated with the clinical course of diseases such as carcinoma (135).  Therefore, we 
stained the Ki67 protein in tumor regions by immunohistochemistry (Fig. 23C). A significantly 
increased fraction of Ki67-positive tumor cells were observed in both CA-Ahr livers (7.3%) and 
CA-AHR livers (12.5%), suggesting a higher proliferation rate. 
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Figure 23. Activation of AHR induced mitosis and increased DNA proliferation. 
Mice were i.p. injected with a single dose of 90 μg/kg DEN at 6-week-old, and liver tissues were 
harvested after 9 months. Shown are representative images from liver tumor sections by H&E staining 
(100×) with dotted lines denoting the nodule areas (A), H&E staining (400×) with arrows indicating cells 
that are undergoing mitosis (B), and immunohistochemistry (400×) stained with the proliferation marker 
Ki67 (C). N=6-11 for each group.  
 
3.4.2 Activation of Human AHR Increased Inflammation and Impaired Liver Function 
after DEN Treatment 
This intriguing finding strongly suggested the carcinogenic effect of AHR activation in humans. 
A connection between chronic inflammation and hepatic carcinogenesis has long been proposed. 
Inflammatory cells and cytokines generated in tumor microenvironment are a major contributing 
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factor to tumor growth, progression, and immunosuppression, and deletion or inhibition of 
inflammatory cytokines inhibits development of experimental cancer (136). Like many tumor 
promoters and nongenotoxic carcinogens, inflammatory cytokines play an important role in 
TCDD-mediated liver tumor promoting events (113). To determine whether activation of human 
AHR plays a role in increasing inflammatory cytokine expressions as observed by others in 
DEN-treated mice (116), we measured the mRNA expressions of IL-6 and TNF-α in the whole 
liver. TNF-α was significantly upregulated in the livers of DEN-exposed CA-AHR mice than in 
WT mice, but not IL-6 (Fig. 24A), suggesting that AHR activation may promote 
proinflammation through increasing the expression of TNF-α after DEN treatment. In the 
inflamed liver, TNF-α is a major effector that binds to the receptors TNFR1 and TNFR2 and 
triggers the transcriptional activation of NF-κB, which is known as a tumor promoter in 
inflammatory-associated cancer (137). The observation that Ahr activation facilitated oxidative 
stress together with the fact that oxidative stress can lead to chronic inflammation (138) also 
suggested the link between AHR activation and inflammation. Common liver functional tests, 
including measurements of serum ALT and AST levels, may be used to predict hepatic 
carcinogenesis risk in general population with unknown risk (139). Both ALT and AST levels 
were significantly increased in mice of both genotypes compared to WT mice (Figure 24B), 
indicating impaired liver function by AHR activation after DEN treatment. 
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Figure 24. Activation of AHR induced TNF-α expression and increased liver injury after DEN 
treatment. 
Mice were i.p. injected with a single dose of 90 μg/kg DEN at 6-week-old and sacrificed after 9 months. 
Livers and serum were collected at the end of the experiment. (A) Hepatic expression of IL-6 and TNF-α. 
(B) Serum concentrations of ALT and AST. N=6-11 for each group. *, P<0.05; **, P<0.01. CA-AHR vs. 
WT, or the comparisons are labled. Results are presented as means ± standard error of the mean (SEM). 
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3.4.3 Growth Arrest and DNA-Damage-Inducible beta (Gadd45b) is Induced by AHR 
Activation 
Comparison of the gene expression profiles has provided important insights in identifying the 
genes that are associated with clinicopathologic features of hepatic carcinogenesis. Of particular, 
dysregulation of cell proliferation is a fundamental aspect of cancer, and this can be caused by 
alternations in cell cycle genes such as Cyclin D, Cyclin E, and cyclin-dependent kinase (Cdk) 
families including Cdk1, Cdk2, Cdk4, and Cdk6 (140). Among these cell cycle genes, Cyclin D1 
and Cdk1 were upregulated by AHR activation in DEN-exposed mice (Fig. 25A). Moreover, the 
proto-oncogene c-Myc encodes a transcription factor that regulates cell proliferation, growth and 
apoptosis (141). Dysregulated expression of c-Myc is one of the most common abnormalities in 
malignant transformation (142). We found that c-Myc expression was significantly higher in 
CA-AHR mice with a 5.5-fold induction compared to WT mice (Fig. 25A). These results 
indicated the malignancy in CA-AHR mice liver, which was also suggested by previous 
histological identification.  
Of note, we  found that the expression of the growth arrest and DNA-damage-inducible 
beta (Gadd45b), a signal molecule inducible to external stress and UV irradiation, was highly 
induced upon AHR activation after DEN exposure (Fig. 25A). Interestingly, Gadd45b was 
reported to promote liver regeneration after partial hepatectomy (143), and its dysregulated 
expression has been observed in multiple types of solid tumors (144, 145). To examine the 
expression profile and the localization of the Gadd45b protein in CA-AHR mice livers that bear 
tumors, we collected their liver tissues from tumors and tumor-surrounding areas and measured 
their mRNA and protein levels. We found significantly increased hepatic Gadd45b mRNA in 
both tumor and non-tumor tissues from CA-AHR mice compared to that in WT mice (Fig. 25B). 
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Also, Gadd45b protein was highly expressed in hepatocytes from both tumor and non-tumor 
areas, and its expression was detected in both cytoplasm and nucleus (Fig. 25C).  
 
 
 
 
Figure 25. AHR activation induced expression of Gadd45b.  
Mice were i.p. injected with a single dose of 90 μg/kg DEN at 6-week-old and sacrificed after 9 months. 
Tumor bearing liver tissues and the surrounding non-tumor tissues were collected. (A) Expressions of 
Gadd45b, c-Myc, and cell cycle related genes in DEN-exposed mice livers. (B and C) are mRNA 
Expression (B) and immunohistochemistry (C) of Gadd45b in liver tissues from tumor-surrounding (N) 
and tumor (T) areas in CA-AHR mice and WT mice. N=6-11 for each group. *, P<0.05; **, P<0.01. 
Results are presented as means ± standard error of the mean (SEM). 
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3.4.4 Gadd45b is An AHR Target Gene 
After observing the dramatic induction of hepatic Gadd45b in DEN-exposed CA-AHR mice, we 
want to know if this induction is AHR responsive. The mRNA expression profile in the non-
challenged 6-week-old CA-AHR mice showed dramatic increase of Gadd45b compared to WT 
mice, whereas other oncogenes (including c-Myc, Cyclin D1, and Cdk1) that are upregulated by 
AHR activation in the tumor settings remained unchanged (Fig. 26A). These results suggested 
that the induction of c-Myc, Cyclin D1, and Cdk1 might be a secondary effect due to the tumor 
microenvironment, whereas Gadd45b upregulation is likely to be an AHR-dependent effect.  
Indeed, the induction of Gadd45b was also observed in WT mice acutely treated with TCDD, but 
this induction was abolished in AHRKO mice (Fig. 26B). Although TCDD treatment seemed to 
induce expression of c-Myc, this increase is still present in AHRKO mice, indicating the c-Myc 
upregulation by TCDD may involve AHR-independent mechanisms (Fig. 26B). Moreover, by 
treating human primary hepatocytes with the human AHR ligand 3-MC, Gadd45b expression 
was significantly induced (Fig. 26C). These results, together with the Gadd45b induction in CA-
AHR mice, strongly suggested Gadd45b as an AHR responsive gene. 
To directly test whether Gadd45b is an AHR target gene, we cloned the Gadd45b gene 
promoter and evaluated its regulation by AHR. Inspection of the Gadd45b promoter revealed 
three putative DREs (Fig. 27A). EMSA confirmed that only the DRE1 was bound by the AHR-
ARNT heterodimer or the CA-AHR-ARNT heterodimer (Fig. 27B). To confirm the recruitment 
of CA-AHR onto the Gadd45b gene promoter in vivo, we performed ChIP assay on cells 
transfected with Flag-CA-AHR. As shown in Fig. 27C, CA-AHR was significantly recruited to 
the DRE1-franking region on Gadd45b gene promoter. The transactivation of the Gadd45b gene 
promoter by AHR was also evaluated by luciferase reporter assays (Fig. 27D). The 1.33-kb 
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Gadd45b gene promoter was transactivated by CA-AHR or AHR in the presence of the AHR 
agonist 3-MC, whereas this activation was partially abolished when the region containing DRE1 
was deleted (Fig. 27D). 
 
 
 
Figure 26. AHR activation induced expression of Gadd45b in an AHR-dependent manner.  
(A) Expressions of Gadd45b, c-Myc, Cyclin D1, and Cdk1 in 6-week-old WT and CA-AHR mice livers 
(N=5 for each group). (B) 8-week old WT and AHRKO male mice (N=5 for each group) were i.p. 
injected with TCDD (10μg/kg) or coin oil for a consecutive 4 days before tissue harvesting. Expressions 
of Gadd45b, c-Myc, Cyclin D1, and Cdk1 were determined in livers. (C) Human primary hepatocytes 
were isolated from human livers and treated with DMSO or 3-MC (4 μM) for 24 hours before harvesting. 
Expressions of Cyp1a2 and Gadd45b were analyzed in triplicate groups. *, P<0.05; **, P<0.01. Results 
are presented as means ± standard error of the mean (SEM). 
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Figure 27. Gadd45b is a direct transcriptional target of AHR.  
(A) Representation of DREs on Gadd45b promoter. (B) The sequence of Gadd45b DRE1 and the mutant 
variant (top) and EMSA result (bottom). (C) ChIP assay to show the recruitment of CA-AHR onto the 
Gadd45b promoters. WT CD-1 mice (N=4 for each group) livers were hydrodynamically transfected with 
pCMX-Flag empty construct or pCMX-Flag-CA-AHR expressing construct. (D) Activation of the 
Gadd45b promoter reporter gene by AHR in the presence of 3-MC, or by CA-AHR without an 
exogenously added ligand. CV1 cells were co-transfected with indicated reporters and receptors. 
Transfected cells were treated with vehicle DMSO or 3-MC (4 μM) for 24 h before luciferase assay in 
triplicate groups. *, P<0.05; **, P<0.01. Results are presented as means ± standard error of the mean 
(SEM). 
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3.4.5 Gadd45b Coactivates AHR-mediated Transcription 
Despite its transcriptional regulation by AHR, Gadd45b was reported to contain two LXXLL 
(where L is leucine and X is any amino acid) signature motifs and act as a coactivator of several 
nuclear receptors (146). Of note, Gadd45b directly binds to the xenobiotic receptor constitutive 
androstane receptor (CAR) and facilitates its transcription activity (134, 147). As a member of 
the bHLH/PAS family of transcription factor, AHR recruits several coactivators (such as SRC-1 
and p300/CBP) and enhances its own transcriptional activity (148). To explore whether Gadd45b 
has a coactivation effect on AHR transcription activity, we co-transfected Gadd45b and AHR 
expression plasmids with the AHR reporter construct pGud-Luc in human hepatoma Huh7 cells. 
Gadd45b dose-dependently induced the reporter activity of pGud-Luc with or without TCDD 
treatment, and this coactivation effect was even more pronounced in AHR-transfected cells (Fig. 
28A). Moreover, hydrodynamic overexpression of Gadd45b in mice liver induced hepatic 
mRNA expressions of CYP1A1 and NRF2, both of which are typical AHR target genes (Fig. 
28B). In mice that received TCDD treatment, Gadd45b exerted a stronger coactivation effect by 
upregulating expression of AHR targets including CYP1A2, CYP1B1, Tiparp, and NRF2 (Fig. 
28B). To determine whether Gadd45b is required for AHR activity, we treated WT and Gadd45b 
knockout (GK) mice with TCDD. We found that AHR target genes remained highly induced by 
TCDD even after Gadd45b was deleted (Fig. 28C), suggesting that other coactivators of AHR, 
such as SRC-1, NCoA-2, and p/CIP (149) might account for the persistent AHR transcription 
activity in the absence of Gadd45b. These observations suggested that Gadd45b is capable of 
facilitating AHR-mediated transcription activity, but may not be solely necessary.  
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Figure 28. Gadd45b coactivates AHR-mediated transcription. 
(A) Luciferase activity of the AHR reporter pGud-Luc. Huh7 cells were cotransfected with Flag-Gadd45b, 
pCMX-AHR, and pGud-luciferase reporter gene and were subsequently treated with DMSO and TCDD 
(10 nM) for 24 h. Luciferase activity was measured in triplicate groups. (B) mRNA levels of AHR target 
genes in CD-1 male mice (N=5 for each group) livers overexpressed with pCMX-Flag or Flag-Gadd45b 
construct and treated with TCDD (10 μg/kg) for 24 h. (C) Hepatic mRNA levels of AHR target genes in 
WT and Gadd45b knockout (GK) mice (N=5 for each group) treated with corn oil and TCDD (10 μg/kg) 
for 24 h. *, P<0.05; **, P<0.01. Results are presented as means ± standard error of the mean (SEM). 
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The co-immunoprecipitation analysis demonstrated direct binding of HA-tagged AHR 
and Flag-tagged Gadd45b, and 3-MC further enhanced the interaction (Fig. 29A). To explore the 
mechanism of their interaction, we utilized the Gal4-VP16 system, in which Gadd45b was fused 
to the Gal4-DBD construct (Gal4-Gadd45b) and Ahr was fused to the VP16-AD construct (Ahr-
VP). The fusion constructs were transfected with the Gal4 reporter gene thymidine kinase-
upstreatm activation sequence (Tk-UAS) in 293T cells. As shown in Fig. 29B, co-transfection of 
Ahr-VP and Gal4-Gadd45b significantly activated the UAS-mediated transcription, whereas 
deletion of the 93-160 domain in Gadd45b abolished this activity. These observations indicated 
that the 93-160 domain in the Gadd45b was required for the Ahr-Gadd45b interaction.  
Having observed the transcriptional regulation of Gadd45b by AHR and the coactivation 
effect of AHR by Gadd45b, we crossbred the CA-AHR mice with GK mice to generate the AHR 
transgenic mice with the deletion of Gadd45b (AGK). The functional relevance of the AHR-
Gadd45b induction in AHR-promoted liver tumor will be explored in the future study.  
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Figure 29. Physical interaction of AHR and Gadd45b. 
(A) Physical interaction of HA-AHR and Flag-Gadd45b in 293T cells by co-immunoprecipitation. HA-
AHR and Flag-Gadd45b plasmids (0.4 μg/well for each) were co-transfected in 6-well 293T cells, and 
cell lysates from three wells were combined for co-IP. (B) Mapping of the Ahr binding domain on 
Gadd45b. Shown are the representation (top) and western blot (middle) of Gal4-Gadd45b constructs using 
antibody against Gal4-DBD, and Tk-UAS reporter activity in 293T cells transfected with the Ahr-VP 
construct and truncated Gal4-Gadd45b constructs (bottom) in triplicate groups. *, P<0.05; **, P<0.01. 
Results are presented as means ± standard error of the mean (SEM). 
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3.5 DISCUSSION 
 
The interpretation of the carcinogenic effect of AHR from animal studies into humans is 
confounded by many different components. First, the primary structure of the AHR protein 
shares limited similarity between human and mouse, conferring distinct ligand binding affinity 
and the variety of the transcriptional activity. Second, humans are relatively resistant to the toxic 
effects by the class of dioxin chemicals represented by TCDD. Additionally, the epidemiological 
evidence regarding carcinogenesis by TCDD has been considered inadequate and limited (129). 
Given the known fact that constitutive activation of the mouse Ahr receptor was able to promote 
liver cancer development, in this study, we attempted to identify the in vivo carcinogenic 
potential of the human AHR in a humanized mouse model to better evaluate the receptor 
mediated human cancer risk assessment.  
For this purpose, we overexpressed the CA-AHR in the mouse background, which 
allowed the constitutive activation of human AHR with no requirement for human AHR 
agonists. This strategy offers a major focus on the AHR receptor rather than different ligand 
efficiency. Surprisingly, in comparison to mice that overexpressed the CA-Ahr, activated human 
AHR also promoted hepatic carcinogenesis in the DEN-initiated two-stage model, and the liver 
tumor promoting efficiency is almost comparable between human and mouse receptor. This 
seems contradictory to the previous report that replacement of the mouse Ahr gene with human 
AHR cDNA conferred mice less sensitive to TCDD-induced toxic effects such as fetal 
teratogenesis (150). This might be largely due to the distinct affinities of mouse and human 
receptor to TCDD. Our model excluded the potential confounder due to inadequate activation of 
human AHR by mouse Ahr agonists such as TCDD. Limited level of the human AHR protein 
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might also account for the attenuated responsiveness of hAHR knock-in mice to TCDD (150). 
There are concerns in humanized AHR mice that the human receptor may not recruit coactivators 
as efficiently as the mouse counterpart (150). But our results that human and mouse AHR 
exerted almost equal carcinogenic effect suggested that the coactivator recruitment might be 
varying during different molecular events. At least in the liver tumor promoting process CA-
AHR was relatively efficient. It is also plausible that the constitutively activated constructs work 
differently from the wild-type constructs in their efficacy of recruiting coactivators. 
A connection between cell apoptosis and cancer has long been proposed. Whether a 
hepatocyte proliferates or dies in response to a genotoxic stress such as DEN will dictate cell fate 
during carcinogenesis. Gadd45b is an anti-apoptotic factor that directly binds to MKK7 and 
inhibits MKK7-dependent phosphorylation of JNK1/2, thereby repressing JNK-mediated 
apoptosis (143). Gadd45b belongs to the small-molecule (~18 kDa) Gadd45 family of inducible 
proteins that play important roles in diverse biological processes including stress response, 
survival, senescence, and apoptosis (151). Notably, a possible role of Gadd45b in 
hepatocarcinogenesis and hepatocyte proliferation has been suggested by establishing Gadd45b 
as a constitutive androgen receptor (CAR)-responsive gene (134). CAR, a xenobiotic nuclear 
receptor, was also reported to be a nongenotoxic tumor promoter that mediates the carcinogenic 
effect of phenobarbital in hepatic carcinogenic development in mice. Interestingly, we found that 
Gadd45b was highly induced in the DEN-challenged CA-AHR mice, suggesting its potential role 
as an AHR responsive gene as well.  
We hypothesized that Gadd45b should exhibit AHR-dependent induction long before the 
liver developed tumors, suggestive by its upregulation in 6-week-old CA-AHR mice as well as in 
mice acutely treated with TCDD. In contrast, we searched a panel of AHR-regulated molecules 
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that may be involved in the promotion of hepatic carcinogenesis, such as c-Myc, Cyclin D1, and 
Cdk1, and we found that they are only induced in the tumor-developing livers, but not in the 
short-term induced models. Therefore, here we have further explored the Gadd45b as a candidate 
of AHR-regulated gene. The AHR-Gadd45b regulation was also suggested in human primary 
hepatocytes treated with the human AHR agonist 3MC, along with the validated DRE on the 
promoter of Gadd45b in both in vitro and in vivo.  
In addition, Gadd45 proteins were reported to act as transcriptional coactivators of 
several nuclear receptor transcription factors (146). The transcription of CAR target genes 
activated by 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) was attenuated in 
Gadd45-/- mice, despite their intact proliferative responses (134). This coactivation effect of 
CAR transcription by Gadd45b was achieved by their direct binding, and TCPOBOP recruited 
both proteins onto the regulatory element of the CAR target gene Cyp2B10 (134).  Another 
xenobiotic receptor, pregnane X receptor (PXR), was also reported to stimulate Gadd45b 
expression and then interacts with the protein after it is expressed (152). Similarly, we found that 
Gadd45b acted as a coactivator of AHR, by showing a dose-dependent coactivation effect of 
Gadd45b in the luciferase activity of AHR reporter gene. Also, transfection of Gadd45b into 
mouse liver further enhanced TCDD-induced AHR transcription by increasing its target gene 
expression. The coactivation effect of Gadd45b was also suggested by the presence of 2 LXXLL 
signature motifs, at amino acid 98 and 117 (134). However, deletion of the LXXLL motifs did 
not block its binding to AHR, an effect also found for its interaction with CAR (134). But 
lacking the half C-terminal (93-160) domain resulted in no interaction, suggesting that both the 
LXXLL motifs and the 126-160 region are required for its interaction with AHR.  
Our results indicated that the AHR-Gadd45b induction might serve as a feed-forward 
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mechanism, by which the synthesis of a coactivator Gadd45b facilitates AHR-mediated 
transcription. The unchanged response of TCDD-induced AHR target gene expression in 
Gadd45b-/- mice could be explained by compensation of other classical AHR coactivators. 
However, the intrinsic biological functions of Gadd45b in stress response and apoptosis led us to 
think that lacking Gadd45b might alter AHR-caused cellular events in the DEN-initiated 
carcinogenic settings. Further studies using AHR transgenic mice lacking the Gadd45b will 
better depict the role of the AHR-Gadd45b axis in liver tumor promoting events.  
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4.0  CHAPTER IV: SUMMARY AND PERSPECTIVES 
In the first part of this thesis work, my results have revealed the role of human AHR in fatty liver 
and energy metabolism as summarized in Fig. 30. Despite the notion that exposure to dioxins 
results in metabolic abnormalities, the transcriptional mechanisms by which AHR affects 
metabolic homeostasis have not been well understood. In our current model, hepatic activation of 
AHR can upregulate the expression of the endocrine hormone FGF21, which can be released into 
circulation and act on extra-hepatic tissues to exert metabolic benefits despite having fatty liver. 
The direct metabolic benefits of FGF21 in adipose tissue are through the FGFR1-βKlotho 
pathway. We propose that FGF21-induced adiponectin production and secretion mediates the 
improved metabolic functions in adipose tissue and skeletal muscle of transgenic mice as well.  
 
Figure 30. Model of the AHR-FGF21 axis in lipid and energy metabolism. 
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Of note, the AHR-FGF21 regulation in the liver seems to be responsible for the hepatic lipid 
droplet formation, and the underlying mechanisms need further study.  
For future studies, whether pharmacological activation of AHR relieves the pre-existing 
obesity and insulin resistance needs to be examined. Our data has suggested that AHR activation 
protects mice from diet-induced obesity and type 2 diabetes, which support the beneficial role of 
AHR in the anti-diabetic effect. On the other hand, studies using AHR null mice also revealed an 
improved phenotype in type 2 diabetes and insulin resistance, suggesting the detrimental role of 
AHR in the diabetic effect. However, both studies have the shortage about the genetic model, 
which is one does not know whether the effects are due to developmental issues or whether they 
occur early in the diabetic process. Additionally, the constitutive activation of AHR or lack of 
the AHR expression makes it difficult to translate into physiological conditions, which may limit 
the data interpretation. Since many endogenous and less-toxic AHR agonists and antagonists 
have been developed, it’s interesting to investigate how these ligands may potentially affect 
energy metabolism through AHR activation or repression. It’s equally interesting to evaluate 
whether metabolic alteration by AHR agonists are opposite to that by AHR antagonists.  
My current study is mainly focused on the hepatic role of AHR activation, and assumes 
the phenotypes observed in extra-hepatic tissues are FGF21-dependent. However, AHR is also 
highly expressed in a variety of other organs, such as lung, intestine, heart, muscle, etc., in which 
AHR signaling may also contribute to the metabolic homeostasis. Generation of other tissue-
specific AHR transgenic mice may help better delineate the contribution of AHR signaling in 
each organ to the overall energy metabolism.   
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In the second part of this thesis work, my results revealed that genetic activation of human AHR 
promoted DEN-initiated liver tumor formation, which is summarized in Fig. 31. The 
carcinogenic effect of TCDD in humans is considered inadequate and limited compared to that in 
rodents, which is largely due to its much weaker ligand binding affinity to human AHR. Here we 
focused on the carcinogenic potential of human AHR receptor itself by overexpressing the 
constitutively-activated human AHR in mouse liver and we found transgenic activation of AHR 
was, as efficiently as its mouse counterpart, in promoting hepatic carcinogenesis. Of note, AHR 
activation upregulates the expression of Gadd45b, a stress inducer with anti-apoptotic effect and 
was found abnormally expressed during carcinogenesis. On the other hand, the induction of 
Gadd45b facilitates AHR transcription activity, which may serve as a feed-forward mechanism 
to potentiate the tumor promoting effect of AHR. Future studies are necessary to determine 
whether the activation of Gadd45 is required for the tumor promoting effect of AHR by 
generating CA-AHR transgenic mice in the Gadd45b null background.  
 
Figure 31. Model of AHR-Gadd45b regulation in hepatic carcinogenesis. 
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Our data has suggested that human AHR activation works as efficiently as mouse 
counterpart in promoting hepatic carcinogenesis when comparing the liver-specific CA-AHR 
transgenic mice to the CA-Ahr transgenic mice. One limitation of the humanized CA-AHR 
transgenic mouse model is that the human receptor might recruit coactivators and corepressors 
differently in the human body compared to that in the mouse background. The lack of ligand 
binding domain in the CA-AHR construct might also lead to differential coregulator recruitment 
compared to the wild type receptor, which will limit the data interpretation.  
Although AHR was first identified as a xenobiotic receptor that mediates dioxin toxicity, 
emerging evidence suggests equally important roles of this receptor in various endobiotic 
functions. Specifically, the roles of AHR in livers were found to be very diverse, with some 
beneficial and some detrimental effects. Gain-of-function of hepatic AHR by TCDD treatment or 
transgenic mice caused liver fibrosis and hepatic carcinogenesis. On the other hand, loss-of-
function of hepatic AHR leads to similar outcomes. In addition, the paradoxical observations that 
AHR has an anti-inflammatory effect in LPS-treated macrophages, whereas it mediates the pro-
inflammatory effect of TCDD in hepatocytes underlines the liver-specific AHR signaling in the 
generation of distinct physiological outcomes. Further studies are needed to determine the cell-
specific function of AHR in different cell types within the liver as well as other organs in various 
physiological and pathophysiological conditions.  
The diverse functions of AHR raise many challenges in developing AHR as a potential 
therapeutic target. To achieve a precise targeting of AHR, cell-specific targeting by conjunction 
of targeting moieties such as antibodies and short peptides that can be recognized by specific 
cells may be required. More importantly, better selective AHR ligands that can specifically target 
the beneficial components with minimal toxicity are needed. One strategy is to develop selective 
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AHR modulators that can differently alter AHR-responsive genes through differential coactivator 
and corepressor recruitment. However, whether or not different ligands can mediate differential 
coregulator recruitment warrants further investigation. Growing interest has been focused on 
developing weak AHR agonists that have moderate affinity for AHR but would not exhibit the 
toxicity of a full agonist, such as TCDD. These selective AHR agonists will exhibit antagonistic 
effect on AHR activity in the presence of a full agonist, but the efficacy of these ligands with 
regard to different physiological settings needs to be evaluated. However, we must be aware that, 
whether it is the use of agonists or antagonists, an efficacious AHR ligand might not fulfill a 
“one size fits all” role in treating different types of diseases.  
Altogether, my thesis work has highlighted the important, although conflicting and 
counterintuitive, aspects of the role of AHR in energy metabolism and hepatic carcinogenesis. 
The humanized AHR transgenic mouse model would serve as a favorable approach for future 
studies in vivo. It is hoped that AHR can be developed as a therapeutic target in human diseases.  
 
 84 
APPENDIX A 
SEQUENCES OF REAL-TIME PCR PRIMERS 
Gene Primer Sequences 
  Forward Reverse 
CYP1A1 GTGCATCGGAGAGACCATTG GGTAGGAGTCATATCCACCTT 
CYP1A2 GCAGTGGAAAGACCCCTTTG CCTTCTCGCTCTGGGTCTTG 
CYP1B1 CTCCAGAGCTTCTCCCAGAT TGGACTGTCTGCACTAAGGC 
IL-6 CCACGGCCTTCCCTACTTC TGGGAGTGGTATCCTCTGTGAA 
VEGF TACTGCTGTACCTCCACCTCCACCATG TCACTTCATGGGACTTCTGCTCT 
TNF-a AAGCCTGTAGCCCACGTCGTA AGGTACAACCCATCGGCTGG 
F4/80 GCTGTGAGATTGTGGAAGCA ATGGCCAAGGCAAGACATAC 
CD68 CCAATTCAGGGTGGAAGAAA CTCGGGCTCTGATGTAGGTC 
PPARa TGTCGAATATGTGGGGACAA AATCTTGCAGCTCCGATCAC 
CPT-1a GCTGCTTCCCCTCACAAGTTCC GCTTTGGCTGCCTGTGTCAGTATGC 
Lcad TCAATGGAAGCAAGGTGTTCA GCCACGACGATCACGAGA 
Mcad TTGAGTTGACGGAACAGCAG CCCCAAAGAATTTGCTTCAA 
Srebp-1c CCCTGTGTGTACTGGCCTTT TTGCGATGTCTCCAGAAGTG 
ACC-1 GCCTCTTCCTGACAAACGAG TGACTGCCGAAACATCTCTG 
SCD-1 TTCTTACACGACCACCACCA CCGAAGAGGCAGGTGTAGAG 
Fas CCCTTGATGAAGAGGGATCA ACTCCACAGGTGGGAACAAG 
Dio2 GATGCTCCCAATTCCAGTGT TGAACCAAAGTTGACCACCA 
Cidea AGGCCGTGTTAAGGAATCTG CCCAGTACTCGGAGCATGTA 
Elovl3 CTTTGCCATCTACACGGATG TGTCTCCCAGTTCAACAACC 
Adiponectin GCACTGGCAAGTTCTACTGCAACA AGAGAACGGCCTTGTCCTTCTTGA 
PGC1a GACTCAGTGTCACCACCGAAA TGAACGAGAGCGCATCCT 
UCP3 ATGAGTTTTGCCTCCATTCG GGCGTATCATGGCTTGAAAT 
FGF21 CTGGGGGTCTACCAAGCATA CACCCAGGATTTGAATGACC 
Plin1 CTCTGGGAAGCATCGAGAAG GCATGGTGTGTCGAGAAAGA 
Plin2 CATTTCTCAGCTCCACTCCA GTAGCCGATGCTTCTCTTCC 
Plin3 CTCAAGCTGCTATGGAGGAACC CATACGTGGAACTGATAAGAGGCA 
Cidec ATCAGAACAGCGCAAGAAGA CAGCTTGTACAGGTCGAAGG 
C-Myc TGACCTAACTCGAGGAGGAGCTGGAA AAGTTTGAGGCAGTTAAAATTATG 
Gadd45b GCCCGAGACCTGCACTGCCT CCATTGGTTATTGCCTCTGCTCTCTT 
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Cyclin D1 TGAGAACAAGCAGACCATCC TGAACTTCACATCTGTGGCA 
Cyclin E AATTGGGGCAATAGAGAAGAGGT TGGAGCTTATAGACTTCGCACA 
Cdk1 TTGGAGAAGGTACTTACGGTGTGGTG CCAGGAGGGATGGAGTCCAGGT 
Cdk2 CCGGCTCGACACTGAGACTGAAG GAGGAATGCCCGTGAGAGCAGA 
Cdk4 TGCTACTGGAAATGCTGACC TCCTTGTGCAGGTAGGAGTG 
Cdk6 GGCCCTTACCTCGGTGGTCGTC GGCCACGTCCCTAGGCCAGTCT 
Tiparp CCAGCTCCAGCTCCAACTAC CTGTAAGAACGGCATCAGCA 
Nrf2 CACATTCCCAAACAAGATGC CTGAACTTTCAGCGTGGCT 
Cyclophilin TGGAGAGCACCAAGACAGACA TGGAGAGCACCAAGACAGACA 
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